+

US20060094783A1 - Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof - Google Patents

Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof Download PDF

Info

Publication number
US20060094783A1
US20060094783A1 US11/155,864 US15586405A US2006094783A1 US 20060094783 A1 US20060094783 A1 US 20060094783A1 US 15586405 A US15586405 A US 15586405A US 2006094783 A1 US2006094783 A1 US 2006094783A1
Authority
US
United States
Prior art keywords
pai
dosage form
pharmaceutical dosage
mao
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/155,864
Inventor
Moussa Youdim
John Finberg
Ruth Levy
Jeffrey Sterling
David Lerner
Tirtsah Berger-Paskin
Haim Yellin
Tzila Yellin
Alex Veinberg
Veinberg Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Technion Research and Development Foundation Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23772591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060094783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL9295290A external-priority patent/IL92952A/en
Application filed by Teva Pharmaceutical Industries Ltd, Technion Research and Development Foundation Ltd filed Critical Teva Pharmaceutical Industries Ltd
Priority to US11/155,864 priority Critical patent/US20060094783A1/en
Publication of US20060094783A1 publication Critical patent/US20060094783A1/en
Priority to US11/595,726 priority patent/US20070100001A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the subject invention is in the field of selective irreversible inhibitors of the enzyme monoamine oxidase (hereinafter MAO) and provides the R(+) enantiomer of N-propargyl-1-aminoindan (also referred to herein as PAI)which is a selective irreversible inhibitor of the B-form of monoamine oxidase enzyme (hereinafter MAO-B).
  • MAO monoamine oxidase
  • PAI N-propargyl-1-aminoindan
  • the subject invention also provides pharmaceutical compositions containing R(+)PAI which are particularly useful for the treatment of Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, and withdrawal. symptoms.
  • Parkinson's disease is widely considered to be the result of degradation of the pre-synaptic dopaminergic neurons in the brain, with a subsequent decrease in the amount of the neurotransmitter dopamine being released. Inadequate dopamine release, therefore, leads to the onset of disturbances of voluntary muscle control, which disturbances are symptomatic of Parkinson's disease.
  • L-DOPA a decarboxylase inhibitor
  • the decarboxylase inhibitor protects the L-DOPA molecule from peripheral decarboxylation and thus ensures L-DOPA uptake by the remaining dopaminergic neurons in the striatum of the brain.
  • the L-DOPA is converted into dopamine resulting in increased levels of dopamine in these neurons.
  • these neurons are therefore capable of releasing larger amounts of dopamine at levels which approximate the normal required levels. L-DOPA treatment thus alleviates the symptoms of the disease and contributes to the well-being of the patient.
  • L-DOPA treatment has its drawbacks, the main one being that its effectiveness is optimal only during the first few years of treatment. After this period, the clinical response diminishes and is accompanied by adverse side effects which include dyskinesia, fluctuation in efficacy throughout the day (“on-off effect”) and psychiatric symptoms such as confusional states, paranoia, and hallucinations.
  • MAO exists in two forms known as MAO-A and MAO-B which are selective for different substrates and inhibitors.
  • MAO-B more efficiently metabolizes substrates such as 2-phenylethylamine, and is selectively and irreversibly inhibited by ( ⁇ )-deprenyl as described below.
  • MAO-B was shown to be the predominant form of MAO in the brain, selective inhibitors for this form are thus considered to be a possible tool for achieving a decrease in dopamine breakdown on the one hand, together with a minimization of the systemic effects of total MAO inhibition on the other.
  • MAO-A and MAO-B are chiral molecules. Although one enantiomer often shows some stereoselectivity in relative potency towards MAO-A and -B, a given enantiomeric configuration is not always more selective than its mirror image isomer in discriminating between MAO-A and MAO-B.
  • Table I lists the IC 50 (mmol/L) of enantiomeric pairs of propargyl amines in a rat brain preparation of MAO. These results show small differences in potency in MAO-B inhibition between the R and S enantiomers. (B. Hazelhoff, et al., Naunyn-Schmeideberg's Arch. Pharmacol., 330, 50 (1985)). Both enantiomers are selective for MAO-B. In 1967, Magyar, et al. reported that R-( ⁇ )-deprenyl is 500 times more potent than the S-(+) enantiomer in inhibiting the oxidative deamination of tyramine by rat brain homogenate. (K. Magyar, et al., Act. Physiol. Acad. Sci., Hung., 32, 377 (1967)).
  • R-deprenyl In rat liver homogenate, R-deprenyl is only 15 times as potent as the S enantiomer. In other pharmacological activity assays, such as for the inhibition of tyramine uptake, deprenyl shows different stereoselectivities. The S form is in certain cases the more potent epimer. (J. Knoll and K. Magyar, Advances in Biochemical Psychopharmacology. 5, 393 (1972)).
  • N-Methyl-N-propargyl-1-aminotetralin (2-MPAT) is a close structural analogue of deprenyl.
  • the absolute stereo-chemistry of 2-MPAT has not been assigned.
  • the (+) isomer is selective for MAO-B and the ( ⁇ ) isomer is selective for MAO-A.
  • the difference in potency between the 2-MPAT enantiomers is less than 5-fold.
  • B. Hazelhoff, et al., id. The enantiomers of N-propargyl-1-aminotetralin (1-PAT) are also similar in activity.
  • Table I shows clear structure-activity relationships between isolated (+) or ( ⁇ )-2-MPAT-makes it impossible to predict the absolute stereochemistry thereof.
  • Brain stroke is the third leading cause of death in the developed countries. Survivors often suffer from neurological and motor disabilities. The majority of CNS strokes are regarded as localized tissue anemia following obstruction of arterial blood flow which causes oxygen and glucose deprivation. Occlusion of the middle cerebral artery in the rat (MCAO) is a common experimental procedure that is assumed to represent stroke in humans. It has been proposed that the neurological lesion caused by proximal occlusion of this artery in the rat corresponds to a large focal cerebral infarct in humans (Yamori et al., 1976). This correspondence has been based on similarities between cranial circulation in the two species. Other animal models of stroke have been described by Stefanovich (1983).
  • ( ⁇ )-deprenyl to a combination of L-DOPA and a decarboxylase inhibitor administered to Parkinsons's patients leads to improvements in akinesia and overall functional capacity, as well as the elimination of “on-off” type fluctuations (reviewed by Birkmayer & Riederer in “Parkinson's Disease,” Springer-Verlag, pp. 138-149 (1983)).
  • ( ⁇ )-deprenyl (a) enhances and prolongs the effect of L-DOPA, and (b) does not increase the adverse effects of L-DOPA treatment.
  • ( ⁇ )-deprenyl is not without its own adverse sides effects, which include activation of pre-existing gastric ulcers and occasional hypertensive episodes.
  • ( ⁇ )-deprenyl is an amphetamine derivative and is metabolized to amphetamine and methamphetamines, which substances may lead to undesirable side effects such as increased heart rate (Simpson, Biochemical Pharmacology, 27, 1951 (1978); Finberg, et al., in “Monoamine Oxidase Inhibitors—The State of the Art,” Youdim and Paykel, eds., Wiley, pp. 31-43 (1981)).
  • Racemic PAI.HCl is a potent, selective, irreversible inhibitor of MAO-B, is not metabolized to amphetamines, and does not give rise to unwanted sympathomimetic effects.
  • racemic PAI was shown to have considerable advantages over ( ⁇ )-deprenyl.
  • racemic PAI produces no significant tachycardia, does not increase blood pressure (effects produced by doses of 5 mg/kg of ( ⁇ )-deprenyl), and does not lead to contraction of nictitating membrane or to an increase in heart rate at doses of up to 5 mg/kg (effects caused by ( ⁇ )-deprenyl at doses over 0.5 mg/kg).
  • racemic PAI.HCl does not potentiate the cardiovascular effects of tyramine (Finberg, et al., in “Enzymes and Neurotransmitters in Mental Disease,” pp.
  • One underlying object of this invention was to separate the racemic PAI compounds and to obtain an enantiomer with MAO-B inhibition activity which would be free of any undesirable side effects associated with the other enantiomer.
  • deprenyl has a similar structure to PAI and it is known that the ( ⁇ )-enantiomer of deprenyl, i.e. ( ⁇ )-deprenyl, is considerably more pharmaceutically active than the (+)-enantiomer, the ( ⁇ ) enantiomer of PAI would be expected to be the more active MAO-B inhibitor.
  • (+)-PAI enantiomer is in fact the active MAO-B inhibitor while the ( ⁇ )-enantiomer shows extremely low MAO-B inhibitory activity. Furthermore, the (+)-PAI enantiomer also has a degree of selectivity for MAO-B inhibition surprisingly higher than that of the corresponding racemic form, and should thus have fewer undesirable side effects in the treatment of the indicated diseases than would the racemic mixture.
  • (+)-PAI has the R absolutet configuration. This finding was also surprising based o the expected structural similarity of (+)-PAI analogy with deprenyl and the amphetamines.
  • (+)-deprenyl was reported to hav activity equal to or even higher than that of the ( ⁇ enantiomer (Tekes, et al., Pol. J. Pharmacol. Pharm., 40 653 (1988)).
  • MPAI is a more potent inhibitor of MAO activity, but wit lower selectivity for MAO-B over A (Tipton, et al., Biochem Pharmacol., 31, 1250 (1982)). As only a small degree o difference in the relative activities of the two resolve enantiomers was surprisingly observed with MPAI, t remarkable behavior of R(+)PAI is further emphasized (S Table 1B).
  • the subject invention also provides methods of using t pharmaceutically active PAI-enantiomer alone (without DOPA) for treatment of Parkinson's disease, a memo: disorder, dementia, depression, hyperactive syndrome, affective illness, a neurodegenerative disease, a neurotox injury, brain ischemia, a head trauma injury, a spin trauma injury, schizophrenia, an attention deficit disorde multiple sclerosis, or withdrawal symptoms (see review Youdim, et al., in Handbook of Experimental Pharmacology, Trendelenberg and Wiener, eds., 90/I, ch. 3 (1988)).
  • the subject invention further provides a method of using the pharmaceutically active PAI-enantiomer alone for pre-treatment of Parkinson's disease.
  • the subject invention also provides pharmaceutical compositions comprising R(+)PAI and synergistic agents such as levodopa.
  • synergistic agents such as levodopa.
  • the use of such agents has been studied with respect to ( ⁇ )-deprenyl which was shown to be effective when administered alone to early Parkinson's patients, and may also have a synergistic effect in these patients when administered together with ⁇ -tocopherol, a vitamin E derivative (The Parkinson's Study Group, New England J. Med., 321(20), 1364-1371 (1989)).
  • ( ⁇ )-deprenyl has also been shown to be useful in the treatment of patients with dementia of the Alzheimer type (DAT) (Tariot, et al., Psychopharmacology, 91, 489-495 (1987)), and in the treatment of depression (Mendelewicz and Youdim, Brit. J. Psychiat. 142, 508-511 (1983)).
  • DAT Alzheimer type
  • the R(+)PAI compound of this invention, and particularly the mesylate salt thereof, has been shown to restore memory.
  • R(+)PAI thus has potential for the treatment of memory disorders, dementia, especially of the Alzheimer's type, and hyperactive syndrome in children.
  • the subject invention provides highly stable salts of R(+)PAI with superior pharmaceutical properties.
  • the mesylate salt is especially stable, shows unexpectedly greater selectivity, and shows significantly fewer side effects than do the corresponding racemic salts.
  • the subject invention further provides a pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan.
  • the subject invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the subject invention further-provides a method of-treating a subject afflicted with Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat Parkinson's disease in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the memory disorder in the subject.
  • the subject invention further provides a method of treating a subject afflicted with dementia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat dementia in the subject.
  • the dementia is of the Alzheimer type (DAT).
  • the subject invention further provides a method of treating a subject afflicted with depression which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat depression in the subject.
  • the subject invention further provides a method of treating a subject afflicted with hyperactive syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat hyperactive syndrome in the subject.
  • the subject invention further provides a method of treating a subject afflicted with an affective illness which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the affective illness in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a neurodegenerative disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurodegenerative disease in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a neurotoxic injury which comprises administering to the subject an amount of R(+)-N-propargyl-3-aminoindan or the pharmaceutically acceptable salt thereof s of the subject invention effective to treat the neurotoxic injury in the subject.
  • the subject invention further provides a method of treating a subject afflicted with brain ischemia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat brain ischemia in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a head trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the head trauma injury in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a spinal trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the spinal trauma injury in the subject.
  • the subject invention further provides a method of treating a subject afflicted with schizophrenia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat schizophrenia in the subject.
  • the subject invention further provides a method of treating a subject afflicted with an attention deficit disorder which comprises administering to the subject an amount of R(+) -N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the attention deficit disorder in the subject.
  • the subject invention further provides a method of treating a subject afflicted with multiple sclerosis which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat multiple sclerosis in the subject.
  • the subject invention further provides a method of preventing nerve damage in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to prevent nerve damage in the subject.
  • the subject invention further provides a method of treating a subject suffering from symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the symptoms of withdrawal in the subject.
  • the subject invention further provides a method for preparing R(+)-N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, R( ⁇ )-aminoindan with either propargyl bromide or propargyl chloride so as to form R(+)-N-propargyl-1-aminoindan, and isolating the R(+)-N-propargyl-1-aminoindan formed thereby.
  • the subject invention further provides a method for preparing racemic N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, racemic 1-aminoindan with propargyl bromide or propargyl chloride so as to form racemic N-propargyl-1-aminoindan, and isolating the racemic N-propargyl-1-aminoindan formed thereby.
  • the subject invention provides a method of preparing an R(+)-N-propargyl-1-aminoindan salt which comprises contacting racemic N-propargyl-1-aminoindan with an optically active acid so as to form two diastereomeric N-propargyl-1-aminoindan salts, and isolating R(+)-N-propargyl-1-aminoindan salt from the diastereomeric N-propargyl-1-aminoindan salts so formed.
  • FIG. 1 is a graphic representation of the results according to Example 22 showing in vitro MAO-A inhibitory activity.
  • FIG. 2 is a graphic representation, of the results according to Example 22 showing in vitro MAO-B inhibitory activity.
  • FIG. 3 is a graphic representation of the results according to Example 22 showing MAO activity in human cortical tissue.
  • FIG. 4 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-A in brain.
  • FIG. 5 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-B in brain.
  • FIG. 6 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-A in liver.
  • FIG. 7 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-B in liver.
  • FIG. 8 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-A in brain.
  • FIG. 9 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-B in brain.
  • FIG. 10 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-A in liver.
  • FIG. 11 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-B in liver.
  • FIG. 12 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-A in brain.
  • FIG. 13 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-B in brain.
  • FIG. 14 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-A in liver.
  • FIG. 15 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-B in liver.
  • FIG. 16 is a graphic representation of the results according to Example 25 showing MAO-B activity in rat brain as a function of time following i.p. administration of R(+)PAI.
  • FIG. 17 is a graphic representation of the results according to Example 32 showing restoration of normokinesia in mice that had received haloperidol 6 mg/kg s.c.
  • Mice received each of the test drugs i.p. at the indicated dose. 2 hours later they received haloperidol.
  • Kinetic scores were taken 3 hours after haloperidol. These scores consisted of the ability to move horizontally along a rod, the ability to descend a vertical rod, and the shortening of catalepsia. In the absence of haloperidol, the maximum score is 12, with haloperidol alone, 6.6 ⁇ 0.03.
  • FIG. 18 is a graphic representation of the results according to Example 32 showing restoration of motor activity in rats treated with ⁇ -methyl-p-tyrosine at 100 mg/kg i.p.
  • Rats received the test drug i.p. at the indicated doses. After two hours they received ⁇ -Mpt and were immediately placed in activity cages. Total motor activity was recorded for the duration of 10 hours.
  • FIG. 19 is a graph showing the NADH response to 2 minutes of anoxia measured 30 minutes after injury and at half-hour intervals thereafter.
  • FIG. 20 Ischemic brain lesion evaluation with MRI T2-scan 48 hours after MCA-O and [R](+)PAI Mesylate Treatment in rats: The middle cerebral artery was surgically occluded as described in Example 38. [R](+)PAI Mesylate was administered as follows: 1.0 mg/kg ip immediately after surgery; 0.5 mg/kg ip, 2 hrs after surgery; 1.0 mg/kg ip, 24 hrs after surgery. Infarct volume (mm 3 ) was determined by MRI 48 hours following surgery.
  • FIG. 21 Neurological evaluation of Wistar rats subjected to MCA-O and [R](+)PAI Mesylate Treatment: The middle cerebral artery was surgically occluded and [R](+)PAI Mesylate administered as in FIG. 20 . At 24 hours post surgery a neurological score was taken as described in Example 38.
  • the subject invention provides R (+)-N-propargyl-1-aminoindan having the structure:
  • R(+)PAI is nearly 7,000 times more active as an inhibitor of MAO-B than is S( ⁇ )PAI.
  • S( ⁇ )PAI is S( ⁇ )PAI.
  • R(+)PAI may be obtained by optical resolution of racemic mixtures of R— and S-enantiomers of PAI.
  • resolution can be accomplished by any conventional resolution method well known to a person skilled in the art, such as those described in J. Jacques, A. Collet and S. Wilen, “Enantiomers, Racemates and Resolutions,” Wiley, New York (1981).
  • the resolution may be carried out by preparative chromatography on a chiral column.
  • Another example of a suitable resolution method is the formation of diastereomeric salts with a chiral acid such as tartaric, malic, mandelic acid or N-acetyl derivatives of amino acids, such as N-acetyl leucine, followed by recrystallisation to isolate the diastereomeric salt of the desired R enantiomer.
  • a chiral acid such as tartaric, malic, mandelic acid or N-acetyl derivatives of amino acids, such as N-acetyl leucine
  • the racemic mixture of R and S enantiomers of PAI may be prepared, for example, as described in GB 1,003,676 and GB 1,037,014.
  • the racemic mixture of PAI can also be prepared by reacting 1-chloroindan with propargylamine.
  • this racemate may be prepared by reacting propargylamine with 1-indanone to form the corresponding imine, followed by reduction of the carbon-nitrogen double bond of the imine with a suitable agent, such as sodium borohydride.
  • the R enantiomer of PAI can also be prepared directly from the optically active R-enantiomer of 1-aminoindan by reaction with propargyl bromide or propargyl chloride in the presence of an organic or inorganic base, and optionally in the presence of a suitable solvent.
  • Suitable organic or inorganic bases for use in the above reaction include, by way of example, triethylamine, pyridine, alkali metal carbonates, and bicarbonates. If the reaction is conducted in the presence of a solvent, the solvent may be chosen from, e.g., toluene, methylene chloride, and acetonitrile.
  • a solvent may be chosen from, e.g., toluene, methylene chloride, and acetonitrile.
  • One method of preparing R(+)PAI is to react R-1-aminoindan with propargyl chloride using potassium bicarbonate as a base and acetonitrile as solvent.
  • the above-described reaction of 1-aminoindan generally results in a mixture of unreacted primary amine, the desired secondary amine and the tertiary amine N,N-bispropargylamino product.
  • the desired secondary-amine i.e., N-propargyl-1-aminoindan
  • a conventional separation method including, by way of example, chromatography, distillation and selective extraction.
  • the R-1-aminoindan starting material can be prepared by methods known in the art which include, by way of example, the method of Lawson and Rao, Biochemistry, 19, 2133 (1980), methods in references cited therein, and the method of European Patent No. 235,590.
  • R-1-aminoindan can also be prepared by resolution of a racemic mixture of the R and S enantiomers, which involves, for example, the formation of diastereomeric salts with chiral acids, or any other known method such as those reported in J. Jacques, et al., ibid.
  • R-1-aminoindan may be prepared by reacting 1-indanone with an optically active amine, followed by reduction of the carbon nitrogen double bond of the resulting imine by hydrogenation over a suitable catalyst, such as palladium on carbon, platinum oxide or Raney nickel.
  • Suitable optically active amines include, for example, one of the antipodes of phenethylamine or an ester of an amino acid, such as valine or phenylalanine.
  • the benzylic N—C bond may be cleaved subsequently by hydrogenation under non-vigorous conditions.
  • R-1-aminoindan is the hydrogenation of indan-1-one oxime ethers as described above, wherein the alkyl portion of the ether contains an optically pure chiral center.
  • a non-chiral derivative of indan-1-one containing a carbon-nitrogen double bond such as an imine or oxime, can be reduced with a chiral reducing agent, e.g., a complex of lithium aluminum-hydride and ephedrine.
  • the subject invention further provides a pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan.
  • pharmaceutically acceptable salts include, but are not limited to, the mesylate, maleate, fumarate, tartrate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salts.
  • the salt is selected from the group consisting of the mesylate salt of R(+)-N-propargyl-1-aminoindan, the esylate salt of R(+)-N-propargyl-1-aminoindan, and the sulfate salt of R(+)-N-propargyl-3-aminoindan.
  • the mesylate salt is highly stable to thermal degradation, and shows unexpectedly superior selectivity for MAO-B over the racemic salt.
  • the free base can be reacted with the desired acids in the presence of a suitable solvent by conventional methods.
  • an acid addition salt may be converted to the free base form in a known manner.
  • a preferred mode of preparing the mesylate salt of (R)-PAI comprises (a) adding an aqueous solution of 15% sodium hydroxide to a solution of propargyl benzenesulfonate (or tosylate or mesylate) in toluene; (b) stirring for 5 hours; (c) adding additional toluene and water; (d) separating and washing the organic phase with 10% sodium hydroxide, and then diluting with water; (e) adjusting the pH of the mixture to 3.2 by adding 10% aqueous sulfuric acid; (f) separating the aqueous phase and adjusting the pH to 7.3 with 10% sodium hydroxide; (g) extracting three times with toluene while maintaining constant pH; (h) concentrating combined organic layers in vacuo to give a yellow oil; (i) dissolving the oil and L-tartaric acid in isopropanol; (j) heating to reflux for 1 hour; (k) cooling to room temperature and collecting the precipitate by filtration
  • the subject invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition which comprises a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • the “therapeutically effective amount” of the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof may be determined according to methods well known to those skilled in the art.
  • Possible salts useful for such compositions include hydrochloride, phosphate, maleate, fumarate, tartrate, mesylate, esylate, and sulfate salts.
  • compositions may be prepared as medicaments to be administered orally, parenterally, rectally, or transdermally.
  • the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet.
  • the therapeutically effective amount may be an amount from about 0.1 mg to about 100 mg.
  • the therapeutically effective amount may also be an amount from about 1 mg to about 10 mg.
  • Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions.
  • the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution.
  • the therapeutically effective amount may be an amount from about 0.1 mg/ml to about 100 mg/ml.
  • the therapeutically effective amount may also be an amount from about 1 mg/ml to about 10 mg/ml.
  • the dose administered is an amount between 0.5 ml and 1.0 ml.
  • the carrier is a gel and the pharmaceutical composition is a suppository.
  • the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion.
  • suppositories with hydrophilic or hydrophobic vehicles.
  • suitable delivery systems as known in the art.
  • the pharmaceutically acceptable salt is a mesylate salt.
  • compositions may be used alone to treat the above-listed disorders, or alternatively, as in the case of Parkinson's disease, for example, they may be used as an adjunct to the conventional L-DOPA treatments.
  • the preferred dosages of the active ingredient, i.e., R-PAI, in the above compositions are within the following ranges.
  • 0.1-100 mg per dosage unit may be taken daily, and preferably 1-10 mg per dosage unit is taken daily.
  • 0.1-100 mg/ml per dosage unit may be taken daily, and preferably 1-10 mg/ml per dosage unit is taken daily.
  • the pharmaceutical composition further comprises a therapeutically effective amount of Levodopa. In another embodiment, the pharmaceutical composition still further comprises an effective amount of a decarboxylase inhibitor.
  • the amount of decarboxylase inhibitor administered in combination with (R)-PAI or a pharmaceutically acceptable salt thereof is an amount effective to ensure L-DOPA uptake in the subject.
  • the decarboxylase inhibitor may be L-Carbidopa.
  • the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg
  • the therapeutically effective amount of Levodopa is about 50 mg to about 250 mg
  • the effective amount of L-Carbidopa is about 10 mg to about 25 mg.
  • the decarboxylase inhibitor may also be benserazide.
  • the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg
  • the therapeutically effective amount of Levodopa is about 50 mg to about 200 mg
  • the effective amount of benserazide is about 12.5 mg to about 50 mg.
  • the subject invention further provides a method of treating a subject afflicted with Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat Parkinson's disease in the subject.
  • the pharmaceutically acceptable salt is a mesylate salt.
  • the administering may comprise orally administering, rectally administering, transdermally administering, or parenterally administering.
  • the method of the subject invention further comprises administering to the subject a therapeutically effective amount of Levodopa. In another embodiment, the method of the subject invention still further comprises administering to the subject an effective amount of a decarboxylase inhibitor.
  • the decarboxylase inhibitor may be L-Carbidopa.
  • the decarboxylase inhibitor may be benserazide.
  • the subject invention further provides a method of treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the memory disorder in the subject.
  • the subject invention further provides a method of treating a subject afflicted with dementia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat dementia in the subject.
  • the dementia is of the Alzheimer type (DAT).
  • the subject invention further provides a method of treating a subject afflicted with depression which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat depression in the subject.
  • the subject invention further provides a method of treating a subject afflicted with hyperactive syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat hyperactive syndrome in the subject.
  • the administering may comprise orally administering, rectally administering, or parenterally administering.
  • the subject invention further provides a method of treating a subject afflicted with an affective illness which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the affective illness in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a neurodegenerative disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurodegenerative disease in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a neurotoxic injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurotoxic injury in the subject.
  • the subject invention further provides a method of treating a subject afflicted with brain ischemia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat brain ischemia in the subject.
  • This invention provides a method of treating brain ischemia or stroke in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat brain ischemia or stroke in the subject.
  • the pharmaceutically acceptable salt of R(*)-N-propargyl-1-aminoindan is selected from the group consisting of: the mesylate salt; the ethylsulfonate salt; the sulfate salt; and the hydrochloride salt.
  • the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan.
  • the effective amount can be determined using techniques known to those of skill in the art, such as titration. In an embodiment of this invention, the effective amount is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject.
  • the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered using techniques known to those of skill in the art. For example, it may be administered intravenously, orally, rectally, transdermally, or parenterally.
  • the subject is preferably a mammal, such as a dog, cat, mouse, rat, rabbit, pig, horse, goat, sheep, cow, ape or monkey. In a particular embodiment the subject is human.
  • the effective amount is from about 0.01 mg to 50.0 mg per day. In a more specific embodiment, the effective amount is from 0.1 to 10.0 mg per day.
  • the area of the brain ischemia is reduced by about thirty-five percent.
  • the subject invention further provides a method of treating a subject afflicted with a head trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the head trauma injury in the subject.
  • the subject invention further provides a method of treating a subject afflicted with a spinal trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the spinal trauma injury in the subject.
  • This invention further provides a method of treating neurotrauma in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat neurotrauma in the subject.
  • the pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan is selected from the group consisting of: the mesylate salt; the ethylsulfonate salt; the sulfate salt; and the hydrochloride salt.
  • the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan.
  • the effective amount can be determined using techniques known to those of skill in the art, such as titration. In an embodiment of this invention, the effective amount is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject.
  • the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered using techniques known to those of skill in the art. For example, it may be administered intravenously, orally, rectally, transdermally, or parenterally.
  • the subject is preferably a mammal, such as a dog, cat, mouse, rat, rabbit, pig, horse, goat, sheep, cow, ape or monkey. In a particular embodiment the subject is human.
  • the effective amount is from about 0.01 mg to 50.0 mg per day. In a more specific embodiment, the effective amount is from 0.1 to 10.0 mg per day.
  • the subject invention further provides a method of treating a subject afflicted with schizophrenia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat schizophrenia in the subject.
  • the subject invention further provides a method of treating a subject afflicted with an attention deficit disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the attention deficit disorder in the subject.
  • the subject invention further provides a method of treating a subject afflicted with multiple sclerosis which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat multiple sclerosis in the subject.
  • the subject invention further provides a method of preventing nerve damage in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to prevent nerve damage in the subject.
  • the nerve damage is structural nerve damage. In another embodiment, the structural nerve damage is optic nerve damage.
  • the subject invention further provides a method of treating a subject suffering from symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the symptoms of withdrawal in the subject.
  • symptoms of withdrawal refers to physical and/or psychological symptoms, including drug craving, depression, irritability, anergia, a motivation, appetite change, nausea, shaking and sleep irregularity.
  • the term “addictive substance” includes, by way of example, (a) addictive opiates such as opium, heroin and morphine, (b) psychostimulants such as cocaine, amphetamines and methamphetamines, (c) alcohol, (d) nicotine, (e) barbiturates and (f) narcotics such as fentanyl, codeine, diphenoxylate and thebaine.
  • the addictive substance is cocaine. In another embodiment, the addictive substance is alcohol.
  • the subject invention further provides a method for preparing R(+)-N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, R( ⁇ )-aminoindan with either propargyl bromide or propargyl chloride so as to form R(+)-N-propargyl-1-aminoindan, and isolating the R(+)-N-propargyl-1-aminoindan formed thereby.
  • the subject invention further provides a method for preparing racemic N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, racemic 1-aminoindan with propargyl bromide or propargyl chloride so as to form racemic N-propargyl-1-aminoindan, and isolating the racemic N-propargyl-1-aminoindan formed thereby.
  • the subject invention provides a method of preparing an R(+) -N-propargyl-1-aminoindan salt which comprises contacting racemic N-propargyl-1-aminoindan with an optically active acid so as to form two diastereomeric N-propargyl-1-aminoindan salts, and isolating R(+)-N-propargyl-1-aminoindan salt from the diastereomeric N-propargyl-1-aminoindan salts so formed.
  • the isolating comprises isolating by fractional crystallization.
  • the title compound in free base form was isolated by resolving the racemic mixture of the free base of Example 1 on a Chiracel OJ (cellulose tris [p-methylbenzoate]) preparative HPLC column eluting with 10% isopropanol/90% hexane and collecting the first eluted major peak.
  • the resulting oil was converted to the title compound (hydrochloride) by treatment of a 10% diethyl ether solution of the oil with gaseous HCl, and the resulting precipitate was collected by suction filtration.
  • Other chromatographic and spectroscopic properties were identical with the hydrochloride salt of Example 1.
  • Example 2 The title compound was prepared as in Example 2 above, except that the second eluted peak from the preparative HPLC was collected: [a] D +29.1° (0.8%, ethanol), m.p. 179-181° C. Other chromatographic and spectroscopic properties were identical with the hydrochloride salt of Example 1.
  • Example 7 The title compound was prepared as in Example 7 above, except that S-( ⁇ )-N-propargyl-1-aminoindan (free base) from Example 5 was used as the starting material. All of the physical and spectral properties of the title compound were identical to those in Example 7 except for the [ ⁇ ] D ⁇ 34.9° C. (ethanol).
  • N-Propargyl-1(R)-aminoindan Hydrochloride 7.81 mg* Pregelatinized starch NF 47.0 mg Lactose NF hydrous 66.0 mg Microcrystalline cellulose NF 20.0 mg Sodium starch glycolate NF 2.99 mg Talc USP 1.5 mg Magnesium stearate NF 0.7 mg *Equivalent to 5.0 mg of N-propargyl aminoindan base.
  • N-Propargyl-1(R)-aminoindan Hydrochloride 1.56 mg* Lactose hydrous 50.0 mg Pregelatinized starch 36.0 mg Microcrystalline cellulose 14.0 mg Sodium starch glycolate 2.14 mg Talc USP 1.0 mg Magnesium stearate NF 0.5 mg *Equivalent to 1.0 mg of N-propargyl aminoindan base.
  • N-Propargyl-1(R)-aminoindan Hydrochloride 5.0 mg Pregelatinized starch 10.0 mg Starch 44.0 mg Microcrystalline cellulose 25.0 mg Ethylcellulose 1.0 mg Talc 1.5 mg Purified water added as required for granulation.
  • N-Propargyl-1(R)-aminoindan Hydrochloride 5.0 mg Dextrose anhydrous 44.0 mg HCl added to pH 5 Purified water added as required for 1 ml
  • N-Propargyl-1(R)-aminoindan Hydrochloride 1.0 mg Sodium chloride 8.9 mg HCl added to pH 5 Purified water added as required for 1 ml
  • N-Propargyl-1(R)-aminoindan Hydrochloride 5.0 mg Sucrose 2250.0 mg Saccarin sodium 5.0 mg Methylparaben 6.0 mg Propylparaben 1.0 mg Flavor 20.0 mg Glycerin USP 500 mg Alcohol 95% USP 200 mg Purified water added as required for 0.5 ml
  • N-Propargyl-1(R)-aminoindan Hydrochloride 2.5 mg Microcrystalline cellulose 20.0 mg Lactose hydrous 5.0 mg Pregelatinized starch 3.0 mg Povidone 0.3 mg Coloring agent q.s. Flavor q.s. Sweetener q.s. Talc 0.3 mg
  • N-Propargyl-1(R)-aminoindan Hydrochloride 5.0 mg Levodopa 100.0 mg Carbidopa 25.0 mg Pregelatinized starch 24.0 mg Starch 40.0 mg Microcrystalline cellulose 49.5 mg Col. D & C Yellow No. 10 0.5 mg Col. D & C Yellow No. 6 0.02 mg Alcohol USP added as required for granulation.
  • N-Propargyl-1(R)-aminoindan Mesylate 7.81 mg* Pregelatinized starch NF 47.0 mg Lactose NF hydrous 66.0 mg Microcrystalline cellulose NF 20.0 mg Sodium starch glycolate NF 2.99 mg Talc USP 1.5 mg Magnesium stearate NF 0.7 mg *Equivalent to 5.0 mg of N-propargyl aminoindan base.
  • N-Propargyl-1(R)-aminoindan Mesylate 1.56 mg* Lactose hydrous 50.0 mg Pregelatinized starch 36.0 mg Microcrystalline cellulose 14.0 mg Sodium starch glycolate 2.14 mg Talc USP 1.0 mg Magnesium stearate NF 0.5 mg *Equivalent to 1.0 mg of N-propargyl aminoindan base.
  • N-Propargyl-1(R)-aminoindan Mesylate 5.0 mg Pregelatinized starch 10.0 mg Starch 44.0 mg Microcrystalline cellulose 25.0 mg Ethylcellulose 1.0 mg Talc 1.5 mg
  • Purified water added as required for granulation.
  • the MAO enzyme source was a homogenate of rat brain in 0.3M sucrose, which was centrifuged at 600 g for 15 minutes. The supernatant was diluted appropriately in 0.05M phosphate buffer, and pre-incubated with serial dilutions of compounds: R(+)-PAI, S( ⁇ )-PAI and racemic PAI for 20 minutes at 37° C. 14 C-Labelled substrates (2-phenylethylamine, hereinafter PEA; 5-hydroxytryptamine, hereinafter 5-HT) were then added, and the incubation continued for a further 20 minutes (PEA), or 30-45 minutes (5-HT). Substrate concentrations used were 50 uM (PEA) and 1 mM (5-HT).
  • the S( ⁇ )-PAI is only 1/6,800 as active as the R(+)PAI for inhibition of MAO-B, and shows little or no selectivity between MAO-B and MAO-A.
  • Rats Male Sprague-Dawley-derived weighing 250 ⁇ 20 g we treated with one of the enantiomers or the racemic form PAI by intraperitoneal injection (ip) or oral gavage (p and decapitated 1 h or 2 h later respectively.
  • Groups three rats were used for each dose level of inhibitor, a MAO activity determined in brain and liver using the gener technique described above.
  • the amount of protein in each incubation was determined using the Folin-Lowry method, a enzyme activity calculated as nmol of substrate metaboli per hour of incubation for each mg of protein.
  • Activity MAO in tissues from animals treated with inhibitors expressed as a percentage of the enzyme activity in a gr of control animals administered vehicle (water for o administration, 0.9% saline for ip injection) and killed as above.
  • Rats (specifications as in Example 23, 4 animals for each dose level) were treated with R(+)PAI or the racemic mixture at three dose levels (0.05, 0.1 and 0.5mg/kg) by oral administration, one dose daily for 21 days, and decapitated 2 hours after the last dose.
  • the activities of MAO types A and B were determined in brain and liver as described in Example 23.
  • a daily dose of 0.1 mg/kg of compound R(+)PAI produced a good degree of selective inhibition, with more than 80% inhibition of brain MAO-B and 20% or less inhibition of brain MAO-A.
  • MAO-A was still inhibited by less than 50% ( FIGS. 12 and 13 ).
  • Hepatic MAO showed a similar degree of selective inhibition ( FIGS. 14 and 15 ).
  • Compound R(+)PAI was again more potent than the racemic mixture by a factor of about twofold. In the case of brain MAO, R(+)PAI had a better degree of selectivity for inhibition of MAO-B than did the racemic mixture.
  • a single dose of compound R(+)PAI (1 mg/kg) was administered by i.p. injection to groups of 4 rats, and the animals killed 2, 6, 18, 24, 48 and 72 hours later.
  • Activity of MAO-B was determined in whole brain tissues as described hereinabove.
  • Rats were anesthetized with a mixture of pentobarbital (30 mg/kg) and chloral hydrate (120 mg/kg) by intraperitoneal injection.
  • the left carotid artery and jugular vein were cannulated with fine polytene tubing (artery) or fine silicone rubber tubing connected to polyethylene tubing (vein), the distal end of which was brought under the skin to an anchor point behind the neck.
  • the tubing was filled with heparinized saline solution, and plugged with a fine steel rod.
  • the animals were treated with 2. mg chloramphenicol by intramuscular injection and allowed to recover from the operation overnight. The following day, the rats were placed in a high-walled container permitting free movement.
  • the arterial catheter was connected to a pressure transducer via a 100 cm length of saline-filled, fine-bore polyethylene tubing, and the venous catheter connected to a 1 ml syringe via a similar length of tubing, which, together with the syringe, contained a solution of tyramine hydrochloride in saline (1 mg/ml). Following an equilibration period of 30 to 40 minutes, tyramine injections (50 or 100 ⁇ g) were given, and blood pressure-responses recorded. An interval of at least 15 minutes was maintained between injections after return of blood pressure to control values.
  • Control pressor responses were established, then one of the drugs was injected intraperitoneally, and tyramine responses were repeated over the next 4 hours.
  • the area under the blood pressure response curve was estimated, and the ratio of this area after treatment to before treatment and to 1 to 3 hours after injection of the compounds, was determined using the average of 3 to 4 values obtained in the control period.
  • MPTP 1-Methyl-phenyl-1,2,3,6-tetrahydropyridine
  • MAO-B inhibitors such as deprenyl or pargyline protects against and prevents the MPTP-induced damage to nigrostriatal neurons because the oxidative conversion of MPTP to MPP+ is blocked.
  • the progressive nigrostriatal degeneration in Parkinson's may be due to exposure to environmentally-derived exogenous MPTP-like neurotoxins.
  • a successful MAO-B inhibitor drug is currently judged by its ability to block MPTP-induced damage to nigrostriatal dopaminergic neurons in vivo.
  • the ( ⁇ ) and (+) enantiomers of PAI were therefore tested for their potency in preventing or attenuating the MPTP-induced striatal dopamine depletions in mice.
  • mice Male C57 black mice (20-25 g weight) were (a) injected with MPTP-HCl (30 mg/kg dissolved in distilled water, s.c.), or vehicle alone, or one hour after pretreatment with the ( ⁇ ) or (+) isomers of PAI (2.5 mg/kg, i.p.), or with deprenyl (5 mg/kg, i.p.), and (b) decapitated 5 days later. Brains were removed and corpora striata dissected on an ice-cold glass plate and frozen on dry ice.
  • Striatal tissues were homogenized in 0.1 M perchloric acid, and deproteinized aliguots containing dihydroxybenzylamine as an internal standard were assayed for dopamine and its major metabolite 3,4-dihydroxy-phenylacetic acid (DOPAC) using HPLC with electrochemical detection.
  • DOPAC 3,4-dihydroxy-phenylacetic acid
  • Table 4 shows the results of this experiment.
  • the (+)-isomer of PAI given before MPTP completely abolished the reduction in striatal DA and DOPAC levels produced by the toxin.
  • (+)PAI was equipotent to ( ⁇ ) deprenyl (5 mg/kg) in its protective effect.
  • (R)-PAI may be combined, in a synergistic way, with ⁇ -tocopherol (a vitamin E derivative) for the treatment of Parkinson's disease.
  • Amphetamine is known to induce stereotypic behavior (Sulser, F., and Sanders-Bush, E., Ann. Rev. Pharmacol., 11, 209-230 (1971)) by the mobilization of endogenous dopamine. Amphetamine is not metabolized by MAO-B. Inhibition of MAO-B by an effective inhibitor and administration of amphetamine cause release of dopamine which will not undergo degradation by the inhibited MAO-B. Thus, an increase of synaptic dopamine is expected after administration of amphetamine and effective MAO-B inhibitor leading to an increase in stereotype behavior-potentiation of the amphetamine effect. The extent of this behavior is rated in accordance with the number of lateral head movements over a period of 1 minute.
  • test compound was administered at a dose of 0.5 mg/kg/day in drinking water, 24 hours before the infliction of hypoxia (92% nitrogen+8S oxygen for 6 hours). Following that, amphetamine was injected s.c. at a dose of 0.5 mg/kg. 45 minutes later, lateral head movements were counted.
  • (+)PAI caused significant potentiation of the amphetamine-induced stereotype behavior in both hypoxia-lesioned and control rats.
  • ( ⁇ )PAI was totally inactive in this respect.
  • Protocol A Nursing mothers were given a dose of either isomer of 1-1.5 mg/kg/day in drinking water until weaning at 21 days. Following that, the weaned offsprings were directly treated with the same dose for 20 days. Treatment was terminated at 40 days and the test was performed at 60 days, that is 20 days after the last dose of the drug.
  • Protocol B The dose was reduced to 0.5 mg/kg/day administered to the nursing mother until weaning at 21 days, then directly to the young rats to 60 days at which time the test was performed.
  • the apparatus consisted of a lit chamber adjoining a dark chamber and a sliding door separating the two. At training, a rat was placed in the lit chamber for 30 seconds, and then the door was opened. The rat moved to the dark chamber with a latency that was recorded. Upon entry of the rat into the dark compartment, the door was closed and a 0.3 mA foot-shock was delivered for 3 seconds.
  • Retention (memory) after 48 hours was determined by repeating the test and recording the latency to step through from light to darkness to an arbitrary maximum of 300 seconds.
  • (+)PAI but not ( ⁇ ) PAI is effective in improving the memory of anoxia-lesioned and control rats.
  • Drugs active in this test are considered to be potentially useful for treatment of various memory impairment disorders, dementia and especially senile dementia of the Alzheimer's type.
  • Anoxia was performed on rat pups on the first post-natal day. They were placed in a glass chamber and exposed to 100% nitrogen for 25 minutes. They were resuscitated by intermittent massage softly applied to the chest and then returned to their respective mothers. Control rats received the same treatment but with air instead of nitrogen.
  • the R(+)-PAI or S( ⁇ )-PAI (0.5 mg/kg/day) was administered to the nursing mothers in drinking water, thereby transferred to the sucklings through milk.
  • Locomotion was measured in 6 fully computerized cages (28 ⁇ 28 cm) by recording the number of crossings over a given period of time. Crossings of grid infrared beams at 4-cm intervals initiated electrical impulses which fed a counter. Recordings of motor activity were made at the ages of 15 and 20 days, over a period of 15 minutes.
  • the figures are the numbers of crossings of infrared beam grid in the activity cage over a period of 15 minutes.
  • Stability is an important factor in the selection of an optimal salt as a therapeutic drug. Different salts may alter the physicochemical and biological characteristics of a drug and can have a dramatic influence on its overall properties. (Berge, S. M., et al., J. Pharm. Sci. 66, 1 (1977); Gould, P. L., Int. J. Pharmaceutics, 33, 201 (1986)).
  • the chromatographic separations were carried out using a Lichrosphere 60 RP select B 5 ⁇ 125 ⁇ 4 mm (Merck) column, an HPLC (Jasco BIP-1) equipped with a L-4200 UV-Vis detector (Merck-Hitachi) set to 210 nm, and a D-2500 chromato-integrator (Merck-Hitachi).
  • the eluent and diluent consisted of 80% distilled water/20% acetonitrile (HPLC grade), and 0.07 M perchloric acid adjusted to pH 2.5 with aqueous ammonia.
  • the flow rate used was 1 ml/min, the appropriate PAI salt solution concentration was 250 ⁇ g/ml, and 20 ⁇ l of the solution were injected onto the chromatographic system.
  • the melting range was measured with an automatic apparatus (Mettler FP 80) and thermo-gravimetric analysis was performed on a Mettler TA 3000 system at a rate of 10° C./min in the applicable range.
  • Solubility was determined by an appropriate dilution of the supernatant from a saturated PAI salt water solution and measured in a UVIKON 941 (Kontron) UV-Vis spectrophotometer.
  • the salt form (mono- or di-salt) was obtained by elemental analysis using standard equipment for C, H, N and S determination.
  • the pH was measured in a 1% aqueous solution of the PAI salts.
  • mice Male, ICR mice 25-30 g each, were pretreated with either of the following drugs: Saline, (R)-PAI mesylate, or racemic-PAI mesylate. All drugs were administered i.p. in a volume of 0.2 mL. Two hours later, haloperidol was injected s.c. at a dose of 6 mg/kg in a volume of 0.1-0.2 mL. Motor coordination tests were made at 3 hours after giving haloperidol, that is, 5 hours after administering the presumed protective drugs.
  • Racemic PAI mesylate conferred partial protection in the range of 7.5-15 mg/kg, and was not active at 5 mg/kg. From FIG. 17 , it can been seen that the dose-effect profile of either (R)-PAI mesylate or racemic PAI is such that an increase in dose beyond 10 mg/kg entails a decrease in effect, but that the racemic mixture is less potent throughout. This means that racemic PAI mesylate at twice the dose of (R)-PAI mesylate will always be less active than the (R) enantiomer.
  • the drug ⁇ -MpT is assumed to inhibit the formation of L-DOPA from tyrosine, and consequently the formation of dopamine itself. Lack of CNS dopamine is expressed as hypoactivity.
  • Six month-old male Wistar rats (from Harlan Orkack, UK) were pretreated with saline, (R)-PAI Mesylate or Rac PAI Mesylate, at the indicated doses. Two hours later they received i.p. ⁇ -MpT at a dose of 100 mg/kg in 0.3-0.5 mL. Controls received saline. Following this, motor activity was recorded in a computerized activity cage for the duration of 10 hours. The results are given in Table 12 and FIG. 18 .
  • (R)-PAI Mesylate restored the level of activity to about 90% of the saline-treated rats, but Rac PAI Mesylate was not active. In either case, the profile of the dose-effect curve was bell-shaped, suggesting a decrease in effect with an increase in dose beyond a peak of 2-5 mg/kg. At 5 mg/kg Rac PAI Mesylate could not elicit a level of activity comparable to that of (R)-PAI Mesylate at 2 mg/kg.
  • (R)-PAI Mesylate and Rac PAI-Mesylate do not share a similar pattern of activity in the restoration of normokinesia in haloperidol-treated mice and ⁇ -Mpt-treated rats.
  • a all doses studied (R)-PAI Mesylate is always more potent that Rac PAI Mesylate at the corresponding dose.
  • peak activity of Rac PAI Mesylate is always lower than peak activity of (R)-PAI Mesylate.
  • Rac PAI Mesylate at a given dose is always less effective than (R)-PAI Mesylate at half the same dose. Doubling the dose of Rac PAI Mesylate with respect to (R)-PAI Mesylate does not produce an effect equivalent to that of (R)-PAI Mesylate.
  • Rh PAI Mesylate cannot be considered as consisting of 50% active ingredient which is (R)-PAI Mesylate and 50% inert material as diluent.
  • the presence of (S)-PAI in Rac PAI Mesylate has an adverse effect on the activity of (R)-PAI, resulting in a more than two-fold decrease in potency. The decrease may be due to a direct adverse effect of (S)-PAI on behavioral parameters.
  • (R)-PAI Mesylate Rac PAI Mesylate Dose, % of % of mg/kg Score + SE n control Score + SE n control 2 14,132** ⁇ 1457 7 89 9,035 ⁇ 829 6 57 5 12,893* ⁇ 1,869 7 81 10,926* ⁇ 820 8 69 7.5 6,679 ⁇ 414 4 42 9,698 ⁇ 557 4 61
  • the scores of (R)-PAI versus racemic PAI are significantly different at 2 mg/kg, p ⁇ 0.01.
  • Head trauma was induced in male rats under ether anesthesia by a well calibrated weight-drop device that falls over the exposed skull, covering the left cerebral hemisphere, 1-2 mm lateral to the midline, in the midcoronal plane.
  • NSS Neurological Severity Score
  • the brains were removed after the second evaluation of motor function (24 h).
  • a piece of tissue ( ⁇ 20 mg) was weighed to yield-wet weight (WW). After drying in a desiccator oven for 24 h at 95° C., it was reweighed to yield dry weight (DW). Water percentage in the tissue was calculated as (WW-DW) ⁇ 100/WW.
  • (R)-PAI Mesylate was dissolved in water.
  • the rats were injected intraperitoneally at a dose of 0.1 mg/kg, 0, 4, 8 and 12 h after induction of head trauma. Control rats were treated with water at the same times.
  • the NSS which measures the “clinical” status of the rats, was almost identical in the treated and nontreated groups at 1 hour after the head injury, but significantly lower at 24 hours in the (R)-PAI mesylate-treated rats (Table 13). These results indicate that PAI mesylate is effective in improving motor function recovery following closed head injury in rats.
  • Procedures cultures of mechanically dissociated neonatal rat cerebellum.
  • the cerebella are dissected aseptically from 6 or 7-day-old rat pups and placed in a 15 ml sterile plastic conic tube containing 3 ml of enriched medium (the medium is made up of Dulbecco's modified Eagle's medium (DMEM) with high glucose concentration (1 g/l), 2 mM (v/v) L-glutamine, antibiotic antimitotic mixture, and enriched with 15% (v/v) heat-inactivated fetal calf serum).
  • DMEM Dulbecco's modified Eagle's medium
  • the cerebella are then dissociated after 20-25 passages through a sterile 13 gauge, 10 cm long stainless steel needle attached to a 5 ml syringe with an inserted 45 ⁇ m pore size nylon sieve.
  • the dissociated cells are centrifuged at 200 g for 5 minutes, the supernatant discarded and the cells resuspended in enriched medium.
  • the cell viability is determined by the trypan blue exclusion test.
  • the cells are then plated at a density of 200/mm 2 on poly-L-lysine-coated surfaces (Poly-L-lysine-coated glass coverslips are prepared at least 1 hour before plating, by immersing in a sterile distilled water solution containing 15 ⁇ g/ml poly-L-lysine, and just before use, washing with sterile water and drying), covered with enriched medium, and incubated at 37° C. in an atmosphere of 5% CO 2 in air and 100% humidity. After 4 days in culture, the media are replaced with media containing the desired test compounds. Experiments are done in duplicate and repeated 2 or 3 times.
  • test compound toxic dose-response After determining the test compound toxic dose-response, four groups are compared: (I) control (enriched medium alone), (II) test compound (one subgroup for each concentration (2 concentrations are tested)), (III) N-methyl-D-aspartate (NMDA, exposure to a concentration of 1 mM for 3 h) as the cytotoxic challenge, (IV) test compound plus NMDA (one subgrcup for each of the 2 concentrations of test compounds), (V) control group to test the effect of solvent (in which the test compound is dissolved), and (VI) an additional “positive control” group of spermine (0.01 ⁇ M dissolved in culture medium) plus NMDA. Nerve cell survival is evaluated by phase contrast microscopy and trypan blue staining after 24 h.
  • glutamic acid possesses neurotoxic properties which are expressed in several neurological disorders including epilepsy and stroke, and most likely also in brain neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and traumatic brain injury.
  • the neurotoxic effects of Glu are mediated by membrane bound Glu receptors such as N-methyl-D-asparate (NMDA) receptors.
  • NMDA N-methyl-D-asparate
  • a special light-guide holder was implanted around the optic nerve in such a way that the light guide was located on the surface of the optic nerve 1 mm distal to the injury site. Animals, while still anesthetized, were allowed to recover for 30 minutes from the surgical procedures and were then exposed to anoxic conditions. An anoxic state was achieved by having the rat breathe in an atmosphere of 100% nitrogen for 2 minutes; after which time it was returned to air. In order to evaluate the metabolic activity of the optic nerve, the relative changes in reflected and fluorescent light intensities in response to anoxia were measured before and after crush injury.
  • Electrophysiological Measurements This method is described by Assia, et al., Brain Res., 476, 205-212 (1989). Animal preparation and optic nerve injury were preferred as in the metabolic studies. Immediately after injury, animals received a single injection of water with or without (R)-PAI Mesylate (0.5 mg/kg). Fourteen days after injury and treatment, the optic nerves were excised and measured electrophysiologically. Prior to removal of optic nerves for electrophysiological measurement, the rats were deeply anesthetized with 70 mg/kg pentobarbitone. The skin was removed from the skull and the optic nerves were detached from the eyeballs. Subtotal decapitation was performed and the skull was opened with a rongeur.
  • the cerebrum was displaced laterally, exposing the intracranial portion of the optic nerve. Dissection was at the level of the nerve, which was transferred to vials containing fresh salt solution consisting of NaCl (126 mM), KCl (3 mM), NaH 2 PO 4 (1.25 mM), NaHCO 3 (26 mM), MgSO 4 (2 mM), CaCl 2 (2 mM), and D-glucose (10 mM), and aerated with 95% O 2 and 5% CO 2 at room temperature.
  • the nerves were kept in this solution, in which electrical activity remained stable for at least 3-4 hours. After 0.5 hours of recovery at room temperature, electrophysiological recordings were obtained from the nerve distal to the crush lesion.
  • the nerve ends were then connected to two suction Ag—AgCl electrodes immersed in a bathing solution at 37° C.
  • a stimulating pulse was applied through the electrode at the proximal end and the action potential was recorded by the distal electrode.
  • a Grass SD9 stimulator was used for supramaximal electrical stimulation (0.5 pps).
  • the measured signal was transmitted to a Medelec PA36 preamplifier and then to an electromyograph (Medelec MS7, AA7T amplifier).
  • the solution, stimulator and amplifier had a common ground.
  • the maximum amplitude of eight averaged compound action potentials (CAPs) was recorded and photographed with a Polaroid camera.
  • the CAP values measured in contralateral uninjured nerves served as a reference.
  • the CAP (compound action potentials) amplitude is directly correlated with the number of conducting fibers in the tested segment of the nerve.
  • (S)-PAI Mesylate has greater anticonvulsant activity than (R)-PAI Mesylate in the MES test. At doses of 100 mg/kg, (S)-PAI Mesylate protected three out of three mice, whereas only one out of three mice was protected with (R)-PAI Mesylate.
  • the MES test is a classical model to indicate efficacy for partial and generalized seizures in humans.
  • the agents' mechanism of action is via their ability to prevent the spread of seizures.
  • Some agents, however, that prevent seizure spread have the side effect of lowering seizure threshold. These agents therefore have both proconvulsive and anticonvulsive side effects.
  • TD 50 Median Toxic Dose
  • Metrazol Test measures the minimal seizure threshold of each animal. Metrazol is infused at 0.185 mg/ml into the tail veins of mice. The time is then recorded (sec) from the start of infusion until the appearance of the first twitch (first focal seizure) and onset of clonus (clonic seizure). Proconvulsants require less Metrazol to produce these symptoms and therefore show endpoints at a shorter period of time.
  • (S)-PAI is much less potent than (R)-PAI as an inhibitor of brain MAO-B. Therefore, (S)-PAI is not a useful agent for the prevention of brain dopamine degradation, but can potentiate the tyramine-evoked release of norepinephrine in the small intestine. Its activity in the small intestine is an undesirable side effect as it is expected to increase the absorption and action of undegraded tyramine. Thus, (S)-PAI is not an inert substance when used together with (R)-PAI as found in racemic PAI.
  • (S)-PAI is almost inactive as a MAO-B inhibitor with respect to (R)-PAI, and hence is not effective in preventing the degradation of brain dopamine. However, it is more effective than R(PAI) in the prevention of the bethanechol-induced contraction of the small intestine. Thus (S)-PAI is not an inert substance when used with R(PAI) as found in racemic PAI.
  • (S)-PAI is inactive with respect to (R)-PAI as a MA inhibitor in the brain, and hence useless for preventing degradation of brain dopamine, but is more active than (R) isomer in causing relaxation of intestinal smo muscle.
  • (S)-PAI is not an inert substance when taken together with the (R)isomer as found in racemic PAI.
  • (S)-PAI is inactive with respect to (R)-PAI as a MAO-B inhibitor in the brain, and hence useless for the prevention of the degradation of brain dopamine, but is more active than the (R) isomer in causing relaxation of intestinal smooth muscle.
  • (S)-PAI is not an inert substance when taken together with the (R) isomer as found in racemic PAI.
  • MCAO Middle cerebral artery occlusion
  • Male Wistar rats (Olac England-Jerusalem) 300-400 g each were anesthetized with a solution of Equitesine administered i.p. at a dose of 3 mL/kg.
  • Equitesine consists of 13.5 mL sodium pentothal solution (60 mg/mL), 3.5 g chloral hydrate, 1.75 g MgSO 4 , 33 mL propylene glycol, 8.3 mL absolute alcohol made up to 83 mL with distilled water.
  • the MCA was severed with microscissors and divided to ensure complete occlusion. Following this, the temporalis muscle was sutured and laid over the craniectomy site. The skin was closed with a running 3-0 silk suture.
  • a shad craniectomy operation was performed on a parallel group of rats, but without cauterization of the MCA.
  • body temperature was maintained at 37 to 38° C. by means of a body-temperature regulator (Kyoristsu, Japan) consisting of a self-regulating heating pad connected to a rectal thermistor.
  • a neurological score was taken in order to assess the severity of the injury in the drug-treated rats with respect to their untreated controls.
  • the animals were anesthetized with Equitesine and the severity of the injury was visualized by an MRI procedure. The volume of brain tissue incurring damage following ischemia was determined.
  • [R](+)PAI Mesylate was administered as an i.p. injection in 0.3-0.4 mL distilled water, according to the following schedule:
  • the size and severity of the infarcted area was estimated using the hyperintensity observed in the T2 weighted MRI at 48 hours post-occlusion or post sham-operation.
  • the following MRI parameters were determined for each group of rats:
  • the neurological score consists of the sum total of a series of ratings assigned to the performance of specific locomotor activities in a given rat.
  • the scale runs from 0 (fully normal rats) to 13 (fully incapacitated rats). Most parameters are rated as either 0 (normal), or 1 (incapacitated); others are graded. The following tests were used in the present study:
  • Rats were lifted by the tail about 15 cm above the floor. Normal rats assume a posture in which they extend both forelimbs towards the floor and spread the hind limbs to the sides in a trapeze-like manner. MCAO when severe causes consistent flexion of the contralateral limb.
  • Gait Ability to restore normal position to either hind contralateral limb when intentionally displaced while on a narrow beam.
  • Locomotor activity Total movements over a period of 15 min in an automated activity cage.
  • the neurological score in five [R](+)PAI Mesylate treated rats and six untreated rats were determined by a blinded observer.
  • the results are given in Table 22 where they are compared with the infarct size in each animal as determined by the MRI test, and also in FIG. 21 . It can be seen that those animals with the least neurological scores were those treated with [R](+)PAI Mesylate.
  • the neurological score was reduced by 54% and the infarct size by 36% in [R](+)PAI Mesylate-treated MCAO rats as compared to untreated ones.
  • TABLE 22 Neurological score of Rats submitted to MCA-Occlusion and [R](+)PAI Mesylate treatment with relation to their ischaemic infarct size.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

Description

  • Throughout this application, various references are referred to. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
    • BACKGROUND OF THE INVENTION
  • I.
  • The subject invention is in the field of selective irreversible inhibitors of the enzyme monoamine oxidase (hereinafter MAO) and provides the R(+) enantiomer of N-propargyl-1-aminoindan (also referred to herein as PAI)which is a selective irreversible inhibitor of the B-form of monoamine oxidase enzyme (hereinafter MAO-B). The subject invention also provides pharmaceutical compositions containing R(+)PAI which are particularly useful for the treatment of Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, and withdrawal. symptoms.
  • II.
  • Parkinson's disease is widely considered to be the result of degradation of the pre-synaptic dopaminergic neurons in the brain, with a subsequent decrease in the amount of the neurotransmitter dopamine being released. Inadequate dopamine release, therefore, leads to the onset of disturbances of voluntary muscle control, which disturbances are symptomatic of Parkinson's disease.
  • Various methods of treating Parkinson's disease have been established and are currently in widespread use, including, for example, the administration of L-DOPA together with a decarboxylase inhibitor such as L-carbidopa or benserazide. The decarboxylase inhibitor protects the L-DOPA molecule from peripheral decarboxylation and thus ensures L-DOPA uptake by the remaining dopaminergic neurons in the striatum of the brain. Here, the L-DOPA is converted into dopamine resulting in increased levels of dopamine in these neurons. In response to physiological impulses, these neurons are therefore capable of releasing larger amounts of dopamine at levels which approximate the normal required levels. L-DOPA treatment thus alleviates the symptoms of the disease and contributes to the well-being of the patient.
  • However, L-DOPA treatment has its drawbacks, the main one being that its effectiveness is optimal only during the first few years of treatment. After this period, the clinical response diminishes and is accompanied by adverse side effects which include dyskinesia, fluctuation in efficacy throughout the day (“on-off effect”) and psychiatric symptoms such as confusional states, paranoia, and hallucinations. This decrease in the effect of L-DOPA treatment is attributed to a number of factors., including the natural progression of the disease, alteration in dopamine receptors as a consequence of increased dopamine production or increased levels of dopamine metabolites, and pharmacokinetic problems of L-DOPA absorption (reviewed by Youdim, et al., Progress in Medicinal Chemistry, 21, 138-167 (1984)).
  • In order to overcome the drawbacks of L-DOPA treatment, various treatments have been devised in which L-DOPA is combined with MAO inhibitors with the aim of reducing the metabolic breakdown of newly formed dopamine (see for example, Chiese, P., U.S. Pat. No. 4,826,875, issued May 2, 1989).
  • MAO exists in two forms known as MAO-A and MAO-B which are selective for different substrates and inhibitors. For example, MAO-B more efficiently metabolizes substrates such as 2-phenylethylamine, and is selectively and irreversibly inhibited by (−)-deprenyl as described below.
  • It should be noted, however, that treatments combining L-DOPA with an inhibitor of both MAO-A and MAO-B are undesirable, as they lead to adverse side effects related to an increased level of catecholamines throughout the neuraxis. Furthermore, complete inhibition of MAO is also undesirable as it potentiates the action of sympathomimetic amines such as tyramine, leading to the so-called “cheese effect” (reviewed by Youdim et al., Handbook of Experimental Pharmacology, ed. by Trendelenburg and Weiner, Springer-Verlag, 90, ch. 3 (1988)). As MAO-B was shown to be the predominant form of MAO in the brain, selective inhibitors for this form are thus considered to be a possible tool for achieving a decrease in dopamine breakdown on the one hand, together with a minimization of the systemic effects of total MAO inhibition on the other.
  • Many inhibitors of MAO are chiral molecules. Although one enantiomer often shows some stereoselectivity in relative potency towards MAO-A and -B, a given enantiomeric configuration is not always more selective than its mirror image isomer in discriminating between MAO-A and MAO-B.
  • Table I lists the IC50 (mmol/L) of enantiomeric pairs of propargyl amines in a rat brain preparation of MAO. These results show small differences in potency in MAO-B inhibition between the R and S enantiomers. (B. Hazelhoff, et al., Naunyn-Schmeideberg's Arch. Pharmacol., 330, 50 (1985)). Both enantiomers are selective for MAO-B. In 1967, Magyar, et al. reported that R-(−)-deprenyl is 500 times more potent than the S-(+) enantiomer in inhibiting the oxidative deamination of tyramine by rat brain homogenate. (K. Magyar, et al., Act. Physiol. Acad. Sci., Hung., 32, 377 (1967)).
  • In rat liver homogenate, R-deprenyl is only 15 times as potent as the S enantiomer. In other pharmacological activity assays, such as for the inhibition of tyramine uptake, deprenyl shows different stereoselectivities. The S form is in certain cases the more potent epimer. (J. Knoll and K. Magyar, Advances in Biochemical Psychopharmacology. 5, 393 (1972)).
  • N-Methyl-N-propargyl-1-aminotetralin (2-MPAT) is a close structural analogue of deprenyl. The absolute stereo-chemistry of 2-MPAT has not been assigned. However, the (+) isomer is selective for MAO-B and the (−) isomer is selective for MAO-A. The difference in potency between the 2-MPAT enantiomers is less than 5-fold. (B. Hazelhoff, et al., id.). The enantiomers of N-propargyl-1-aminotetralin (1-PAT) are also similar in activity. The lack of data in Table I showing clear structure-activity relationships between isolated (+) or (−)-2-MPAT-makes it impossible to predict the absolute stereochemistry thereof.
  • After extensive computer modeling, Polymeropoulos recently predicted that (R)-N-methyl-N-propargyl-1-aminoindan (R-1-MPAI) would be more potent than (S) as a MAO-B inhibitor. (E. Polymeropoulos, Inhibitors of Monoamine Oxidase B, I. Szelenyi, ed., Birkhauser Verlag, p. 110 (1993)). However, experiments described show that R-1-MPAI is a'slightly more potent inhibitor of MAO-B than S-1-MPAI, but is an even more potent inhibitor of MAO-A. Both the selectivity between MAO-A and -B and the relative potency of the R and S-epimers are low. Thus, contrary to expectations in the art, 1-MPAI is useless as a pharmaceutical agent.
  • The data presented below demonstrate that high selectivity for MAO of one enantiomer versus the other cannot be predicted. The structure of the MAO active site is not well enough understood to permit the prediction of the relative potency or selectivity of any given compound or pair of enantiomers thereof.
  • III.
  • Brain stroke is the third leading cause of death in the developed countries. Survivors often suffer from neurological and motor disabilities. The majority of CNS strokes are regarded as localized tissue anemia following obstruction of arterial blood flow which causes oxygen and glucose deprivation. Occlusion of the middle cerebral artery in the rat (MCAO) is a common experimental procedure that is assumed to represent stroke in humans. It has been proposed that the neurological lesion caused by proximal occlusion of this artery in the rat corresponds to a large focal cerebral infarct in humans (Yamori et al., 1976). This correspondence has been based on similarities between cranial circulation in the two species. Other animal models of stroke have been described by Stefanovich (1983).
  • The histological changes described by Tamura et al. (1981) who were the first to introduce the MCAO procedure, were commonly seen in the cortex of the frontal (100%), sensimotor (75%) and auditory (75%) areas and to a lesser extent in the occipital lobe cortex (25%). In addition, damage was observed in the lateral segment of the caudate nucleus (100%), and only to a variable extent in its medial portion (38%). Concomitantly, the following disorders were reported in MCAO animals: neurological deficits (Menzies et al., 1992), cognitive disturbances (Yamamoto et al., 1988), brain edema (Young et al., 1993; Matsui et al., 1993; Saur et al., 1993), decreased cerebral blood flow (Teasdale et al., 1983), catecholamine fluctuations. (Cechetto et al., 1989). Any of these disorders might be indicative of the severity and extent of brain damage that follow MCAO in the rat. Conversely, a drug with a potential to limit or abort a given disorder may be considered as a candidate for the treatment of stroke in humans.
    TABLE IA
    IC50 (mmol/L) Data for Rat Brain MAO Inhibition by
    Propargylamines
    RELATIVE
    INHIBITION POTENCY
    COMPOUND REF EPIMER A B A/B A B
    +/−
    2-MPAI a + 140 16 8.8 3 0.2
    − 46 88 0.5
    R/S
    DEPRENYL a S 3600 16 120
    R 450 6 75 80 2.6
    1-MPAI b S 70 50 1.4 23 5
    R 3 10 0.3
    1-PAT c S 3800 50 76 4 0.5
    R 900 90 10

    a. B. Hazelhoff, et al., Naunyn-Schmeideberg's Arch. Pharmacol., 330, 50 (1985).

    b. European Patent Application 436, 492 A2, published Jul. 10, 1991.

    c. Present inventors.
  • One selective MAO-B inhibitor, (−)-deprenyl, has been extensively studied and used as a MAO-B inhibitor to augment L-DOPA treatment. This treatment with (−)-deprenyl is generally favorable and does not cause the “cheese effect” at doses causing nearly complete inhibition of MAO-B (Elsworth, et al., Psychopharmacology, 57, 33 (1978)). Furthermore, the addition of (−)-deprenyl to a combination of L-DOPA and a decarboxylase inhibitor administered to Parkinsons's patients leads to improvements in akinesia and overall functional capacity, as well as the elimination of “on-off” type fluctuations (reviewed by Birkmayer & Riederer in “Parkinson's Disease,” Springer-Verlag, pp. 138-149 (1983)). Thus, (−)-deprenyl (a) enhances and prolongs the effect of L-DOPA, and (b) does not increase the adverse effects of L-DOPA treatment.
  • However, (−)-deprenyl is not without its own adverse sides effects, which include activation of pre-existing gastric ulcers and occasional hypertensive episodes. Furthermore, (−)-deprenyl is an amphetamine derivative and is metabolized to amphetamine and methamphetamines, which substances may lead to undesirable side effects such as increased heart rate (Simpson, Biochemical Pharmacology, 27, 1951 (1978); Finberg, et al., in “Monoamine Oxidase Inhibitors—The State of the Art,” Youdim and Paykel, eds., Wiley, pp. 31-43 (1981)).
  • Other compounds have been described that are selective irreversible inhibitors of MAO-B but which are free of the undesirable effects associated with (−)-deprenyl. One such compound, namely N-propargyl-1-aminoindan.HCl (racemic PAI.HCl), was described in GB 1,003,686 and GB 1,037,014 and U.S. Pat. No. 3,513,244, issued May 19, 1970. Racemic PAI.HCl is a potent, selective, irreversible inhibitor of MAO-B, is not metabolized to amphetamines, and does not give rise to unwanted sympathomimetic effects. I
  • n comparative animal tests, racemic PAI was shown to have considerable advantages over (−)-deprenyl. For example, racemic PAI produces no significant tachycardia, does not increase blood pressure (effects produced by doses of 5 mg/kg of (−)-deprenyl), and does not lead to contraction of nictitating membrane or to an increase in heart rate at doses of up to 5 mg/kg (effects caused by (−)-deprenyl at doses over 0.5 mg/kg). Furthermore, racemic PAI.HCl does not potentiate the cardiovascular effects of tyramine (Finberg, et al., in “Enzymes and Neurotransmitters in Mental Disease,” pp. 205-219 (1980), Usdin, et al., Eds., Wiley, New York; Finberg, et al. (1981), in “Monoamine Oxidase Inhibitors—The State of the Art,” ibid.; Finberg and Youdim, British Journal Pharmacol., 85, 451 (1985)).
  • One underlying object of this invention was to separate the racemic PAI compounds and to obtain an enantiomer with MAO-B inhibition activity which would be free of any undesirable side effects associated with the other enantiomer.
  • Since deprenyl has a similar structure to PAI and it is known that the (−)-enantiomer of deprenyl, i.e. (−)-deprenyl, is considerably more pharmaceutically active than the (+)-enantiomer, the (−) enantiomer of PAI would be expected to be the more active MAO-B inhibitor.
  • However, contrary to such expectations, upon resolution of the enantiomers, it was found that the (+)-PAI enantiomer is in fact the active MAO-B inhibitor while the (−)-enantiomer shows extremely low MAO-B inhibitory activity. Furthermore, the (+)-PAI enantiomer also has a degree of selectivity for MAO-B inhibition surprisingly higher than that of the corresponding racemic form, and should thus have fewer undesirable side effects in the treatment of the indicated diseases than would the racemic mixture. These findings are based on both in vitro and in vivo experiments as discussed in greater detail infra.
  • It was subsequently shown that (+)-PAI has the R absolutt
    Figure US20060094783A1-20060504-P00999
    configuration. This finding was also surprising based o
    Figure US20060094783A1-20060504-P00999
    the expected structural similarity of (+)-PAI analogy with deprenyl and the amphetamines.
  • The high degree of stereoselectivity of pharmacologica
    Figure US20060094783A1-20060504-P00999
    activity between R(+)-PAI and the S(−) enantiomer a discussed hereinbelow is also remarkable. The compoun
    Figure US20060094783A1-20060504-P00999
    R(+)-PAI is nearly four orders of magnitude more active tha
    Figure US20060094783A1-20060504-P00999
    the S(−) enantiomer in MAO-B inhibition. This ratio i
    Figure US20060094783A1-20060504-P00999
    significantly higher than that observed between the tw
    Figure US20060094783A1-20060504-P00999
    deprenyl enantiomers (Knoll and Magyar, Adv. Biochem Psychopharmacol., 5, 393 (1972); Magyar, et al., Act Physiol. Acad. Sci. Hung., 32, 377 (1967)). Furthermore, in some physiological tests, (+)-deprenyl was reported to hav
    Figure US20060094783A1-20060504-P00999
    activity equal to or even higher than that of the (−
    Figure US20060094783A1-20060504-P00999
    enantiomer (Tekes, et al., Pol. J. Pharmacol. Pharm., 40 653 (1988)).
  • MPAI is a more potent inhibitor of MAO activity, but wit lower selectivity for MAO-B over A (Tipton, et al., Biochem Pharmacol., 31, 1250 (1982)). As only a small degree o
    Figure US20060094783A1-20060504-P00999
    difference in the relative activities of the two resolve enantiomers was surprisingly observed with MPAI, t
    Figure US20060094783A1-20060504-P00999
    remarkable behavior of R(+)PAI is further emphasized (S
    Figure US20060094783A1-20060504-P00999
    Table 1B).
  • The subject invention also provides methods of using t
    Figure US20060094783A1-20060504-P00999
    pharmaceutically active PAI-enantiomer alone (without
    Figure US20060094783A1-20060504-P00999
    DOPA) for treatment of Parkinson's disease, a memo: disorder, dementia, depression, hyperactive syndrome,
    Figure US20060094783A1-20060504-P00999
    affective illness, a neurodegenerative disease, a neurotox injury, brain ischemia, a head trauma injury, a spin trauma injury, schizophrenia, an attention deficit disorde
    Figure US20060094783A1-20060504-P00999
    multiple sclerosis, or withdrawal symptoms (see review Youdim, et al., in Handbook of Experimental Pharmacology, Trendelenberg and Wiener, eds., 90/I, ch. 3 (1988)).
  • The subject invention further provides a method of using the pharmaceutically active PAI-enantiomer alone for pre-treatment of Parkinson's disease. The subject invention also provides pharmaceutical compositions comprising R(+)PAI and synergistic agents such as levodopa. The use of such agents has been studied with respect to (−)-deprenyl which was shown to be effective when administered alone to early Parkinson's patients, and may also have a synergistic effect in these patients when administered together with α-tocopherol, a vitamin E derivative (The Parkinson's Study Group, New England J. Med., 321(20), 1364-1371 (1989)).
  • In addition to its usefulness in treating Parkinson's disease, (−)-deprenyl has also been shown to be useful in the treatment of patients with dementia of the Alzheimer type (DAT) (Tariot, et al., Psychopharmacology, 91, 489-495 (1987)), and in the treatment of depression (Mendelewicz and Youdim, Brit. J. Psychiat. 142, 508-511 (1983)). The R(+)PAI compound of this invention, and particularly the mesylate salt thereof, has been shown to restore memory. R(+)PAI thus has potential for the treatment of memory disorders, dementia, especially of the Alzheimer's type, and hyperactive syndrome in children.
  • Finally, the subject invention provides highly stable salts of R(+)PAI with superior pharmaceutical properties. The mesylate salt is especially stable, shows unexpectedly greater selectivity, and shows significantly fewer side effects than do the corresponding racemic salts.
    • SUMMARY OF THE INVENTION
  • The subject invent ion provides R (+)-N-propargyl-1-aminoindan having the structure:
    Figure US20060094783A1-20060504-C00001
  • The subject invention further provides a pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan.
  • The subject invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • The subject invention further-provides a method of-treating a subject afflicted with Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat Parkinson's disease in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the memory disorder in the subject.
  • The subject invention further provides a method of treating a subject afflicted with dementia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat dementia in the subject. In one embodiment, the dementia is of the Alzheimer type (DAT).
  • The subject invention further provides a method of treating a subject afflicted with depression which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat depression in the subject.
  • The subject invention further provides a method of treating a subject afflicted with hyperactive syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat hyperactive syndrome in the subject.
  • The subject invention further provides a method of treating a subject afflicted with an affective illness which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the affective illness in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a neurodegenerative disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurodegenerative disease in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a neurotoxic injury which comprises administering to the subject an amount of R(+)-N-propargyl-3-aminoindan or the pharmaceutically acceptable salt thereof s of the subject invention effective to treat the neurotoxic injury in the subject.
  • The subject invention further provides a method of treating a subject afflicted with brain ischemia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat brain ischemia in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a head trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the head trauma injury in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a spinal trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the spinal trauma injury in the subject.
  • The subject invention further provides a method of treating a subject afflicted with schizophrenia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat schizophrenia in the subject.
  • The subject invention further provides a method of treating a subject afflicted with an attention deficit disorder which comprises administering to the subject an amount of R(+) -N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the attention deficit disorder in the subject.
  • The subject invention further provides a method of treating a subject afflicted with multiple sclerosis which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat multiple sclerosis in the subject.
  • The subject invention further provides a method of preventing nerve damage in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to prevent nerve damage in the subject.
  • The subject invention further provides a method of treating a subject suffering from symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the symptoms of withdrawal in the subject.
  • The subject invention further provides a method for preparing R(+)-N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, R(−)-aminoindan with either propargyl bromide or propargyl chloride so as to form R(+)-N-propargyl-1-aminoindan, and isolating the R(+)-N-propargyl-1-aminoindan formed thereby.
  • The subject invention further provides a method for preparing racemic N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, racemic 1-aminoindan with propargyl bromide or propargyl chloride so as to form racemic N-propargyl-1-aminoindan, and isolating the racemic N-propargyl-1-aminoindan formed thereby.
  • Finally, the subject invention provides a method of preparing an R(+)-N-propargyl-1-aminoindan salt which comprises contacting racemic N-propargyl-1-aminoindan with an optically active acid so as to form two diastereomeric N-propargyl-1-aminoindan salts, and isolating R(+)-N-propargyl-1-aminoindan salt from the diastereomeric N-propargyl-1-aminoindan salts so formed.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a graphic representation of the results according to Example 22 showing in vitro MAO-A inhibitory activity.
  • FIG. 2 is a graphic representation, of the results according to Example 22 showing in vitro MAO-B inhibitory activity.
  • FIG. 3 is a graphic representation of the results according to Example 22 showing MAO activity in human cortical tissue.
  • FIG. 4 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-A in brain.
  • FIG. 5 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-B in brain.
  • FIG. 6 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-A in liver.
  • FIG. 7 is a graphic representation of the results according to Example 23 showing acute inhibition (i.p.) of MAO-B in liver.
  • FIG. 8 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-A in brain.
  • FIG. 9 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-B in brain.
  • FIG. 10 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-A in liver.
  • FIG. 11 is a graphic representation of the results according to Example 23 showing acute inhibition (per os) of MAO-B in liver.
  • FIG. 12 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-A in brain.
  • FIG. 13 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-B in brain.
  • FIG. 14 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-A in liver.
  • FIG. 15 is a graphic representation of the results according to Example 24 showing chronic inhibition of MAO-B in liver.
  • FIG. 16 is a graphic representation of the results according to Example 25 showing MAO-B activity in rat brain as a function of time following i.p. administration of R(+)PAI.
  • FIG. 17 is a graphic representation of the results according to Example 32 showing restoration of normokinesia in mice that had received haloperidol 6 mg/kg s.c. Mice received each of the test drugs i.p. at the indicated dose. 2 hours later they received haloperidol. Kinetic scores were taken 3 hours after haloperidol. These scores consisted of the ability to move horizontally along a rod, the ability to descend a vertical rod, and the shortening of catalepsia. In the absence of haloperidol, the maximum score is 12, with haloperidol alone, 6.6±0.03. Statistical significance was calculated by the Student's “t” test: * p≦0.05; ** p≦0.01; ***p≦0.001 with respect to haloperidol alone. The scores of (R)-PAI are significantly different from those of racemic-PAI at 5 mg/kg (p≦0.05), at 10 mg/kg (p≦0.01), and at 15 mg/kg (p≦0.05), (n=5.6). The dosage shown is for the free base of PAI (and not the mesylate salt).
  • FIG. 18 is a graphic representation of the results according to Example 32 showing restoration of motor activity in rats treated with α-methyl-p-tyrosine at 100 mg/kg i.p. Rats received the test drug i.p. at the indicated doses. After two hours they received α-Mpt and were immediately placed in activity cages. Total motor activity was recorded for the duration of 10 hours. Control rats, treated with saline, only scored 15,862*1424. With α-Mpt alone, they scored 8,108±810. Statistical significance by the Student's “t” test: *p≦0.05; **p≦0.01; ***p≦0.001 with respect to α-MpT alone. The scores of (R)-PAI are significantly different from racemic-PAI at 2 mg/kg (p≦0.01), (n=6). Dosage shown is for the free base of PAI and not the mesylate salt.
  • FIG. 19 is a graph showing the NADH response to 2 minutes of anoxia measured 30 minutes after injury and at half-hour intervals thereafter.
  • FIG. 20: Ischemic brain lesion evaluation with MRI T2-scan 48 hours after MCA-O and [R](+)PAI Mesylate Treatment in rats: The middle cerebral artery was surgically occluded as described in Example 38. [R](+)PAI Mesylate was administered as follows: 1.0 mg/kg ip immediately after surgery; 0.5 mg/kg ip, 2 hrs after surgery; 1.0 mg/kg ip, 24 hrs after surgery. Infarct volume (mm3) was determined by MRI 48 hours following surgery.
  • FIG. 21: Neurological evaluation of Wistar rats subjected to MCA-O and [R](+)PAI Mesylate Treatment: The middle cerebral artery was surgically occluded and [R](+)PAI Mesylate administered as in FIG. 20. At 24 hours post surgery a neurological score was taken as described in Example 38.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The subject invention provides R (+)-N-propargyl-1-aminoindan having the structure:
    Figure US20060094783A1-20060504-C00002
  • As demonstrated in the Experimental Examples hereinbelow, R(+)PAI is nearly 7,000 times more active as an inhibitor of MAO-B than is S(−)PAI. In view of known MAO-B inhibitors in the art which possess low selectivity between MAO-A and MAO-B, and which do not show predictable trends in potency as a function of R or S configuration, the selectivity of R(+)PAI is unexpected.
  • R(+)PAI may be obtained by optical resolution of racemic mixtures of R— and S-enantiomers of PAI. Such a resolution can be accomplished by any conventional resolution method well known to a person skilled in the art, such as those described in J. Jacques, A. Collet and S. Wilen, “Enantiomers, Racemates and Resolutions,” Wiley, New York (1981). For example, the resolution may be carried out by preparative chromatography on a chiral column. Another example of a suitable resolution method is the formation of diastereomeric salts with a chiral acid such as tartaric, malic, mandelic acid or N-acetyl derivatives of amino acids, such as N-acetyl leucine, followed by recrystallisation to isolate the diastereomeric salt of the desired R enantiomer.
  • The racemic mixture of R and S enantiomers of PAI may be prepared, for example, as described in GB 1,003,676 and GB 1,037,014. The racemic mixture of PAI can also be prepared by reacting 1-chloroindan with propargylamine. Alternatively, this racemate may be prepared by reacting propargylamine with 1-indanone to form the corresponding imine, followed by reduction of the carbon-nitrogen double bond of the imine with a suitable agent, such as sodium borohydride.
  • In accordance with this invention, the R enantiomer of PAI can also be prepared directly from the optically active R-enantiomer of 1-aminoindan by reaction with propargyl bromide or propargyl chloride in the presence of an organic or inorganic base, and optionally in the presence of a suitable solvent.
  • Suitable organic or inorganic bases for use in the above reaction include, by way of example, triethylamine, pyridine, alkali metal carbonates, and bicarbonates. If the reaction is conducted in the presence of a solvent, the solvent may be chosen from, e.g., toluene, methylene chloride, and acetonitrile. One method of preparing R(+)PAI is to react R-1-aminoindan with propargyl chloride using potassium bicarbonate as a base and acetonitrile as solvent.
  • The above-described reaction of 1-aminoindan generally results in a mixture of unreacted primary amine, the desired secondary amine and the tertiary amine N,N-bispropargylamino product. The desired secondary-amine, i.e., N-propargyl-1-aminoindan, can be separated from this mixture by a conventional separation method including, by way of example, chromatography, distillation and selective extraction.
  • The R-1-aminoindan starting material can be prepared by methods known in the art which include, by way of example, the method of Lawson and Rao, Biochemistry, 19, 2133 (1980), methods in references cited therein, and the method of European Patent No. 235,590.
  • R-1-aminoindan can also be prepared by resolution of a racemic mixture of the R and S enantiomers, which involves, for example, the formation of diastereomeric salts with chiral acids, or any other known method such as those reported in J. Jacques, et al., ibid. Alternatively, R-1-aminoindan may be prepared by reacting 1-indanone with an optically active amine, followed by reduction of the carbon nitrogen double bond of the resulting imine by hydrogenation over a suitable catalyst, such as palladium on carbon, platinum oxide or Raney nickel. Suitable optically active amines include, for example, one of the antipodes of phenethylamine or an ester of an amino acid, such as valine or phenylalanine. The benzylic N—C bond may be cleaved subsequently by hydrogenation under non-vigorous conditions.
  • An additional method for preparing R-1-aminoindan is the hydrogenation of indan-1-one oxime ethers as described above, wherein the alkyl portion of the ether contains an optically pure chiral center. Alternatively, a non-chiral derivative of indan-1-one containing a carbon-nitrogen double bond, such as an imine or oxime, can be reduced with a chiral reducing agent, e.g., a complex of lithium aluminum-hydride and ephedrine.
  • The subject invention further provides a pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan.
  • In the practice of this invention, pharmaceutically acceptable salts include, but are not limited to, the mesylate, maleate, fumarate, tartrate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salts.
  • In one embodiment, the salt is selected from the group consisting of the mesylate salt of R(+)-N-propargyl-1-aminoindan, the esylate salt of R(+)-N-propargyl-1-aminoindan, and the sulfate salt of R(+)-N-propargyl-3-aminoindan.
  • As demonstrated in the Experimental Examples hereinbelow, the mesylate salt is highly stable to thermal degradation, and shows unexpectedly superior selectivity for MAO-B over the racemic salt.
  • For the preparation of pharmaceutically acceptable acid addition salts of the compound of R(+)PAI, the free base can be reacted with the desired acids in the presence of a suitable solvent by conventional methods. Similarly, an acid addition salt may be converted to the free base form in a known manner.
  • A preferred mode of preparing the mesylate salt of (R)-PAI comprises (a) adding an aqueous solution of 15% sodium hydroxide to a solution of propargyl benzenesulfonate (or tosylate or mesylate) in toluene; (b) stirring for 5 hours; (c) adding additional toluene and water; (d) separating and washing the organic phase with 10% sodium hydroxide, and then diluting with water; (e) adjusting the pH of the mixture to 3.2 by adding 10% aqueous sulfuric acid; (f) separating the aqueous phase and adjusting the pH to 7.3 with 10% sodium hydroxide; (g) extracting three times with toluene while maintaining constant pH; (h) concentrating combined organic layers in vacuo to give a yellow oil; (i) dissolving the oil and L-tartaric acid in isopropanol; (j) heating to reflux for 1 hour; (k) cooling to room temperature and collecting the precipitate by filtration; (1) recrystallizing the crude di-propargylaminoindan tartrate from methanol/isopropanol (1:1) to give di(R(+)-N-propargyl-1-aminoindan) tartrate; (m) dissolving the tartrate salt and methanesulfonic acid in isopropanol, and heating to reflux for 30 minutes; and (n) cooling to room temperature, and collecting the precipitated R(+)-N-propargyl-1-1-aminoindan.
  • The subject invention further provides a pharmaceutical composition which comprises a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The “therapeutically effective amount” of the R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof may be determined according to methods well known to those skilled in the art.
  • Possible salts useful for such compositions include hydrochloride, phosphate, maleate, fumarate, tartrate, mesylate, esylate, and sulfate salts.
  • These compositions may be prepared as medicaments to be administered orally, parenterally, rectally, or transdermally.
  • In one embodiment, the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet. The therapeutically effective amount may be an amount from about 0.1 mg to about 100 mg. The therapeutically effective amount may also be an amount from about 1 mg to about 10 mg.
  • Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions.
  • In an alternative embodiment, the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution. The therapeutically effective amount may be an amount from about 0.1 mg/ml to about 100 mg/ml. The therapeutically effective amount may also be an amount from about 1 mg/ml to about 10 mg/ml. In one embodiment, the dose administered is an amount between 0.5 ml and 1.0 ml.
  • In a further alternative embodiment, the carrier is a gel and the pharmaceutical composition is a suppository.
  • For parenteral administration the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion. For rectal administration there are provided suppositories with hydrophilic or hydrophobic vehicles. For topical application as ointments and transdermal delivery there are provided suitable delivery systems as known in the art.
  • In the preferred embodiment, the pharmaceutically acceptable salt is a mesylate salt.
  • These compositions may be used alone to treat the above-listed disorders, or alternatively, as in the case of Parkinson's disease, for example, they may be used as an adjunct to the conventional L-DOPA treatments.
  • The preferred dosages of the active ingredient, i.e., R-PAI, in the above compositions are within the following ranges. For oral or suppository formulations, 0.1-100 mg per dosage unit may be taken daily, and preferably 1-10 mg per dosage unit is taken daily. For injectable formulations, 0.1-100 mg/ml per dosage unit may be taken daily, and preferably 1-10 mg/ml per dosage unit is taken daily.
  • In one embodiment, the pharmaceutical composition further comprises a therapeutically effective amount of Levodopa. In another embodiment, the pharmaceutical composition still further comprises an effective amount of a decarboxylase inhibitor.
  • The amount of decarboxylase inhibitor administered in combination with (R)-PAI or a pharmaceutically acceptable salt thereof is an amount effective to ensure L-DOPA uptake in the subject.
  • The decarboxylase inhibitor may be L-Carbidopa. In one embodiment, the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, the therapeutically effective amount of Levodopa is about 50 mg to about 250 mg, and the effective amount of L-Carbidopa is about 10 mg to about 25 mg.
  • The decarboxylase inhibitor may also be benserazide. In one embodiment, the therapeutically effective amount of R(+)-N-propargyl-1-aminoindan is about 0.1 mg to about 100 mg, the therapeutically effective amount of Levodopa is about 50 mg to about 200 mg, and the effective amount of benserazide is about 12.5 mg to about 50 mg.
  • The subject invention further provides a method of treating a subject afflicted with Parkinson's disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat Parkinson's disease in the subject.
  • Methods of treatment of Parkinson's disease which combine the use of (R)-PAI with other drugs, such as dopamine agonists, bromocryptine, pergolide, lisuride, as well as catecholamine oxidase methyl transferase inhibitors are within the scope of the subject invention.
  • In the preferred embodiment, the pharmaceutically acceptable salt is a mesylate salt.
  • The administering may comprise orally administering, rectally administering, transdermally administering, or parenterally administering.
  • In one embodiment, the method of the subject invention further comprises administering to the subject a therapeutically effective amount of Levodopa. In another embodiment, the method of the subject invention still further comprises administering to the subject an effective amount of a decarboxylase inhibitor.
  • The decarboxylase inhibitor may be L-Carbidopa. Alternatively, the decarboxylase inhibitor may be benserazide.
  • The subject invention further provides a method of treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the memory disorder in the subject.
  • The subject invention further provides a method of treating a subject afflicted with dementia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat dementia in the subject. In one embodiment, the dementia is of the Alzheimer type (DAT).
  • The subject invention further provides a method of treating a subject afflicted with depression which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat depression in the subject.
  • The subject invention further provides a method of treating a subject afflicted with hyperactive syndrome which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat hyperactive syndrome in the subject.
  • The administering may comprise orally administering, rectally administering, or parenterally administering.
  • The subject invention further provides a method of treating a subject afflicted with an affective illness which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the affective illness in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a neurodegenerative disease which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurodegenerative disease in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a neurotoxic injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the neurotoxic injury in the subject.
  • The subject invention further provides a method of treating a subject afflicted with brain ischemia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat brain ischemia in the subject.
  • This invention provides a method of treating brain ischemia or stroke in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat brain ischemia or stroke in the subject.
  • In an embodiment of the method for treatment of brain ischemia or stroke, the pharmaceutically acceptable salt of R(*)-N-propargyl-1-aminoindan is selected from the group consisting of: the mesylate salt; the ethylsulfonate salt; the sulfate salt; and the hydrochloride salt. Preferably, the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan.
  • The effective amount can be determined using techniques known to those of skill in the art, such as titration. In an embodiment of this invention, the effective amount is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject. The R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered using techniques known to those of skill in the art. For example, it may be administered intravenously, orally, rectally, transdermally, or parenterally.
  • The subject is preferably a mammal, such as a dog, cat, mouse, rat, rabbit, pig, horse, goat, sheep, cow, ape or monkey. In a particular embodiment the subject is human.
  • In an embodiment of this invention, the effective amount is from about 0.01 mg to 50.0 mg per day. In a more specific embodiment, the effective amount is from 0.1 to 10.0 mg per day.
  • In one embodiment of the above-described method, the area of the brain ischemia is reduced by about thirty-five percent.
  • The subject invention further provides a method of treating a subject afflicted with a head trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the head trauma injury in the subject.
  • The subject invention further provides a method of treating a subject afflicted with a spinal trauma injury which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the spinal trauma injury in the subject.
  • This invention further provides a method of treating neurotrauma in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof effective to treat neurotrauma in the subject.
  • In the treatment of head trauma injury, spinal trauma injury or neurotrauma, the pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan is selected from the group consisting of: the mesylate salt; the ethylsulfonate salt; the sulfate salt; and the hydrochloride salt. Preferably, the pharmaceutically acceptable salt is the mesylate salt of R(+)-N-propargyl-1-aminoindan.
  • The effective amount can be determined using techniques known to those of skill in the art, such as titration. In an embodiment of this invention, the effective amount is from about 0.5 milligrams per kilogram body weight of the subject to about 2.5 milligrams per kilogram body weight of the subject. The R(+)-N-propargyl-1-aminoindan or pharmaceutically acceptable salt thereof is administered using techniques known to those of skill in the art. For example, it may be administered intravenously, orally, rectally, transdermally, or parenterally.
  • The subject is preferably a mammal, such as a dog, cat, mouse, rat, rabbit, pig, horse, goat, sheep, cow, ape or monkey. In a particular embodiment the subject is human.
  • In an embodiment of this invention, the effective amount is from about 0.01 mg to 50.0 mg per day. In a more specific embodiment, the effective amount is from 0.1 to 10.0 mg per day.
  • The subject invention further provides a method of treating a subject afflicted with schizophrenia which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat schizophrenia in the subject.
  • The subject invention further provides a method of treating a subject afflicted with an attention deficit disorder which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the attention deficit disorder in the subject.
  • The subject invention further provides a method of treating a subject afflicted with multiple sclerosis which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat multiple sclerosis in the subject.
  • The subject invention further provides a method of preventing nerve damage in a subject which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to prevent nerve damage in the subject.
  • In one embodiment, the nerve damage is structural nerve damage. In another embodiment, the structural nerve damage is optic nerve damage.
  • The subject invention further provides a method of treating a subject suffering from symptoms of withdrawal from an addictive substance which comprises administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt thereof of the subject invention effective to treat the symptoms of withdrawal in the subject.
  • As used herein, the term “symptoms of withdrawal” refers to physical and/or psychological symptoms, including drug craving, depression, irritability, anergia, a motivation, appetite change, nausea, shaking and sleep irregularity.
  • As used herein, the term “addictive substance” includes, by way of example, (a) addictive opiates such as opium, heroin and morphine, (b) psychostimulants such as cocaine, amphetamines and methamphetamines, (c) alcohol, (d) nicotine, (e) barbiturates and (f) narcotics such as fentanyl, codeine, diphenoxylate and thebaine.
  • In one embodiment, the addictive substance is cocaine. In another embodiment, the addictive substance is alcohol.
  • The subject invention further provides a method for preparing R(+)-N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, R(−)-aminoindan with either propargyl bromide or propargyl chloride so as to form R(+)-N-propargyl-1-aminoindan, and isolating the R(+)-N-propargyl-1-aminoindan formed thereby.
  • The subject invention further provides a method for preparing racemic N-propargyl-1-aminoindan which comprises contacting, in the presence of an organic or inorganic base, racemic 1-aminoindan with propargyl bromide or propargyl chloride so as to form racemic N-propargyl-1-aminoindan, and isolating the racemic N-propargyl-1-aminoindan formed thereby.
  • Finally, the subject invention provides a method of preparing an R(+) -N-propargyl-1-aminoindan salt which comprises contacting racemic N-propargyl-1-aminoindan with an optically active acid so as to form two diastereomeric N-propargyl-1-aminoindan salts, and isolating R(+)-N-propargyl-1-aminoindan salt from the diastereomeric N-propargyl-1-aminoindan salts so formed.
  • In one embodiment, the isolating comprises isolating by fractional crystallization.
  • The following Experimental Details are set forth to aid in an understanding of the invention, and are not intended, and should not be construed, to limit in any way the invention set forth in the claims which follow thereafter.
    • Experimental Details EXAMPLE 1 Racemic N-propargyl-1-aminoindan hydrochloride
  • 10.0 g of racemic 1-aminoindan and 10.4 g of potassium carbonate were added to 75 ml of acetonitrile. T*ee resulting suspension was heated to 60° C. and 4.5 g of propargyl chloride was added dropwise.
  • The mixture was stirred at 60° C. for 16 hours, whereafter most of the volatiles were removed by distillation in vacuo. The residue was partitioned between 10% aqueous sodium hydroxide and methylene chloride.
  • The organic phase was dried and the solvent removed by distillation. The residue was flash chromatographed on silica gel, eluting with 40% ethyl acetate/60% hexane. The fractions containing the title compound as a free base were combined and the eluant replaced by ether. The ethereal solution was treated with gaseous HCl, the precipitate formed was isolated by suction filtration and recrystallized from isopropanol to yield 7.3 g of the title compound, m.p. 182-4° C.
  • Chromatographic and spectroscopic data were in accordance with U.S. Pat. No. 3,513,244, issued May 19, 1970, and an authentic sample, and were as follows: NMR δ (CDCl3): 2.45 (2H, m), 2.60 (1H, t), 2.90 (1H, m), 3.45 (1H, m), 3.70 (2H, d), 4.95 (1H, t), 7.5 (4H, m) ppm.
    • EXAMPLE 2 S-(−)-N-Propargyl-1-aminoindan hydrochloride
  • The title compound in free base form was isolated by resolving the racemic mixture of the free base of Example 1 on a Chiracel OJ (cellulose tris [p-methylbenzoate]) preparative HPLC column eluting with 10% isopropanol/90% hexane and collecting the first eluted major peak. The resulting oil was converted to the title compound (hydrochloride) by treatment of a 10% diethyl ether solution of the oil with gaseous HCl, and the resulting precipitate was collected by suction filtration. [a]D−29.2° (1%, ethanol), m.p. 182-184° C. Other chromatographic and spectroscopic properties were identical with the hydrochloride salt of Example 1.
    • EXAMPLE 3 R-(+)-N-Propargyl-1-aminoindan hydrochloride
  • The title compound was prepared as in Example 2 above, except that the second eluted peak from the preparative HPLC was collected: [a]D+29.1° (0.8%, ethanol), m.p. 179-181° C. Other chromatographic and spectroscopic properties were identical with the hydrochloride salt of Example 1.
    • EXAMPLE 4 R-(+)-N-Propargyl-1-aminoindan hydrochloride
  • 12.4 g of R-(−)-1-Aminoindan and 12.9 g of potassium carbonate were added to 95 ml of acetonitrile. The resulting suspension was heated to 60° C. and 5.6 g of propargyl chloride was added dropwise. The mixture was stirred at 60° C. for 16 hours, whereafter most of the volatiles were removed by distillation in vacuo. the residue was partitioned between 10% aqueous sodium hydroxide and methylene chloride.
  • The organic phase was dried and the solvent removed in vacuo. The residue was flash chromatographed on silica get eluting with 40% ethyl acetate/60% hexane. Fractions containing the free base of the title compound were combined and the solvent replaced by ether. The ethereal solution was treated with gaseous HCl and the resulting precipitate was isolated by suction filtration and recrystallized from isopropanol to yield 6.8 g of the title compound, m.p. 183-185° C., [a]D+30.90 (2% ethanol). Spectral properties were identical to those reported for the compound of Example 1.
    • EXAMPLE 5 S-(−)-N-Propargyl-1-aminoindan hydrochloride
  • The title compound was prepared by the method of Example 4, except that S-(+)-1-aminoindan was used as starting material. The product exhibited [a]D−30.3. (2% ethanol), m.p. 183-5° C. Spectral properties were identical to those reported for the compound of Example 1.
    • EXAMPLE 6A Di(R-(+)-N-propargyl-1-aminoindan) L-tartrate
  • To a solution of tartaric acid (4.4 g) in 48 ml of boiling methanol was added a solution of R-(+)-N-propargyl-1-aminoindan free base (5.09) in methanol (48 ml). The solution was heated to reflux and 284 ml of t-butylmethyl ether was added over 20 minutes. The mixture was heated for an additional 30 minutes, cooled, and the resulting precipitate was isolated by suction filtration to yield 6.7 g of the title compound: m.p. 175-177° C.; [α]D(1.5, H2O)=+34.3; Anal. calcd. for C28H32O6N2; C, 68.26; H, 6.56; N, 5.69. Found: C, 68.76; H, 6.57; N, 5.61.
    • EXAMPLE 6B R-(+)-N-propargyl-1-aminoindan mesylate
  • a) To a solution of propargyl benzenesulfonate (78.4 g) and racemic aminoindan (63.2 g) in toluene (240 mL) at 20° C. was added dropwise an aqueous solution of 15% sodium hydroxide (108 mL). After 5 hours of stirring, additional toluene (80 mL) and water (200 mL) were added with stirring. The organic phase was separated and washed with 10% aqueous sodium hydroxide and then diluted with water. The pH of the mixture was adjusted to 3.2 by the addition of 10% aqueous sulfuric acid. The aqueous phase was separated and its pH was adjusted to 7.3 with 10% sodium hydroxide and extracted three times with toluene while maintaining constant pH. The combined organic layers were concentrated in vacuo to 40.7 g of a yellow oil.
  • b) The above crude racemic propargylaminoindan and L-tartaric acid (10 g) were dissolved in isopropanol (1 L) and heated to reflux for 1 hour. The reaction was then allowed to cool to room temperature with stirring and the precipitate collected by filtration. The crude di-propargylaminoindan tartrate was recrystallized from 1 L of 1:1 methanol/isopropanol to give di(R—(+)—N-propargyl-1-aminoindan)-L-tartrate with physical and spectral properties identical to that of the compound of Example 6A.
  • c) A solution -of di-(R—(+)—N-propargyl-1-aminoindan) tartrate (15 g) and methanesulfonic acid (6 g) in isopropanol (150 mL) was heated to reflux for 30 minutes. The reaction was allowed to cool to room temperature and the resulting precipitate isolated by suction filtration to give the title compound (11.1 g) with m.p. 157° C. and [α]D=22°.
    • EXAMPLE 7 R-(+)-N-Methyl-N-propargyl-1-aminoindan hydrochloride
  • The free base form of R-(+)-N-propargyl-1-aminoindan from Example 4 (1.2 grams), potassium carbonate (0.97 grams) and methyl iodide (1 gram) were added to 15 ml of acetone and the resulting suspension heated to reflux under a nitrogen atmosphere for 8 hours. Thereafter the volatiles were removed under reduced pressure and the residue partitioned between 10% aqueous sodium hydroxide (30 ml) and methylene chloride (30 ml). The organic phase was dried and the solvent removed in vacuo. The residue was flash chromatographed on silica gel eluting with 40% ethyl acetate/60% hexane. Fractions containing the title compound as a free base were combined and the solvent replaced by diethyl ether. The etheral solution was treated with gaseous HCl. The volatiles were removed in vacuo, and the residue recrystallized from isopropanol to yield 400 mg of the title compound as a white crystalline solid, m.p. 134-136° C., [α]D+31.40 (ethanol). NMR δ (CDCl3): 2.55 (2H, m); 2.7 (1H, br.s); 2.8 (3H, s); 3.0 (1H, m); 3.4 (1H, m); 3.9 (2H, br.s); 5.05 (1H, m); 7.7 (4H, m) ppm.
    • EXAMPLE 8 S-(−)-N-Methyl-N-propargyl-1-aminoindan hydrochloride
  • The title compound was prepared as in Example 7 above, except that S-(−)-N-propargyl-1-aminoindan (free base) from Example 5 was used as the starting material. All of the physical and spectral properties of the title compound were identical to those in Example 7 except for the [α]D−34.9° C. (ethanol).
    • EXAMPLE 9 Tablet Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride  7.81 mg*
    Pregelatinized starch NF 47.0 mg
    Lactose NF hydrous 66.0 mg
    Microcrystalline cellulose NF 20.0 mg
    Sodium starch glycolate NF 2.99 mg
    Talc USP  1.5 mg
    Magnesium stearate NF  0.7 mg

    *Equivalent to 5.0 mg of N-propargyl aminoindan base.
    • EXAMPLE 10 Tablet Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride  1.56 mg*
    Lactose hydrous 50.0 mg
    Pregelatinized starch 36.0 mg
    Microcrystalline cellulose 14.0 mg
    Sodium starch glycolate 2.14 mg
    Talc USP  1.0 mg
    Magnesium stearate NF  0.5 mg

    *Equivalent to 1.0 mg of N-propargyl aminoindan base.
    • EXAMPLE 11 Capsule Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride  5.0 mg
    Pregelatinized starch 10.0 mg
    Starch 44.0 mg
    Microcrystalline cellulose 25.0 mg
    Ethylcellulose  1.0 mg
    Talc  1.5 mg

    Purified water added as required for granulation.
    • EXAMPLE 12 Injection Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride  5.0 mg
    Dextrose anhydrous 44.0 mg

    HCl added to pH 5

    Purified water added as required for 1 ml
    • EXAMPLE 13 Injection Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride 1.0 mg
    Sodium chloride 8.9 mg

    HCl added to pH 5

    Purified water added as required for 1 ml
    • EXAMPLE 14 Injection Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride 2.0 mg
    Sodium chloride 8.9 mg

    HCl added to pH 5

    Purified water added as required for 1 ml
    • EXAMPLE 15 Syrup Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride   5.0 mg
    Sucrose 2250.0 mg
    Saccarin sodium   5.0 mg
    Methylparaben   6.0 mg
    Propylparaben   1.0 mg
    Flavor   20.0 mg
    Glycerin USP   500 mg
    Alcohol 95% USP   200 mg

    Purified water added as required for 0.5 ml
    • EXAMPLE 16 Sublingual Tablets
  • N-Propargyl-1(R)-aminoindan Hydrochloride 2.5 mg
    Microcrystalline cellulose 20.0 mg 
    Lactose hydrous 5.0 mg
    Pregelatinized starch 3.0 mg
    Povidone 0.3 mg
    Coloring agent q.s.
    Flavor q.s.
    Sweetener q.s.
    Talc 0.3 mg
  • Blend the excipients and the active and granulate with an ethanol solution of Providone. After drying and weighing, it is blended with the talc and compressed.
    • EXAMPLE 17
  • PAI Sublingual Tablets
    N-Propargyl-1(R)-aminoindan Hydrochloride  5.0 mg
    Microcrystalline cellulose 15.0 mg
    Pregelatinized starch 12.0 mg
    Ethyl cellulose  0.3 mg
    Talc  0.3 mg

    Purified water added as required for granulation.
    • EXAMPLE 19 Tablet Composition
  • N-Propargyl-1(R)-aminoindan Hydrochloride  5.0 mg
    Levodopa 100.0 mg 
    Carbidopa 25.0 mg
    Pregelatinized starch 24.0 mg
    Starch 40.0 mg
    Microcrystalline cellulose 49.5 mg
    Col. D & C Yellow No. 10  0.5 mg
    Col. D & C Yellow No. 6 0.02 mg

    Alcohol USP added as required for granulation.
    • EXAMPLE 19 Tablet Composition
  • N-Propargyl-1(R)-aminoindan Mesylate  7.81 mg*
    Pregelatinized starch NF 47.0 mg
    Lactose NF hydrous 66.0 mg
    Microcrystalline cellulose NF 20.0 mg
    Sodium starch glycolate NF 2.99 mg
    Talc USP  1.5 mg
    Magnesium stearate NF  0.7 mg

    *Equivalent to 5.0 mg of N-propargyl aminoindan base.
    • EXAMPLE 20 Tablet Composition
  • N-Propargyl-1(R)-aminoindan Mesylate  1.56 mg*
    Lactose hydrous 50.0 mg
    Pregelatinized starch 36.0 mg
    Microcrystalline cellulose 14.0 mg
    Sodium starch glycolate 2.14 mg
    Talc USP  1.0 mg
    Magnesium stearate NF  0.5 mg

    *Equivalent to 1.0 mg of N-propargyl aminoindan base.
    • EXAMPLE 21 Capsule Composition
  • N-Propargyl-1(R)-aminoindan Mesylate  5.0 mg
    Pregelatinized starch 10.0 mg
    Starch 44.0 mg
    Microcrystalline cellulose 25.0 mg
    Ethylcellulose  1.0 mg
    Talc  1.5 mg
  • Purified water added as required for granulation.
  • The following Examples and the accompanying Tables and Figures relate to biological experiments carried out in accordance with this invention.
    • EXAMPLE 22 Inhibition of MAO activity in vitro Experimental protocol
  • The MAO enzyme source was a homogenate of rat brain in 0.3M sucrose, which was centrifuged at 600 g for 15 minutes. The supernatant was diluted appropriately in 0.05M phosphate buffer, and pre-incubated with serial dilutions of compounds: R(+)-PAI, S(−)-PAI and racemic PAI for 20 minutes at 37° C. 14C-Labelled substrates (2-phenylethylamine, hereinafter PEA; 5-hydroxytryptamine, hereinafter 5-HT) were then added, and the incubation continued for a further 20 minutes (PEA), or 30-45 minutes (5-HT). Substrate concentrations used were 50 uM (PEA) and 1 mM (5-HT). In the case of PEA, enzyme concentration was chosen so that not more than 10% of the substrate was metabolized during the course of the reaction. The reaction was then stopped by addition of tranylcypromine (to a final concentration of 1 mM), and the incubate filtered over a small column of Amberlite CG-50 buffered to pH 6.3. The column was washed with 1.5 ml water, the eluates pooled and the radioactive content determined by liquid scintillation spectrometry. Since the amine substrates are totally retained on the column, radioactivity in the eluate indicates the production of neutral and acidic metabolites formed as a result of MAO activity. Activity of MAO in the sample was expressed as a percentage of control activity in the absence of inhibitors after subtraction of appropriate blank values. The activity determined using PEA as substrate is referred to as MAO-B, and that determined using 5-HT as MAO-A.
  • Results
  • Inhibitory activity of R(+)-PAI, S(−)-PAI and racemic-PAI were examined separately in vitro, and the results of typical experimental runs are shown in FIGS. 1 and 2. The entire experiment was repeated three times. Concentrations of inhibitor producing 50% inhibition of substrate metabolism (IC-50) were calculated from the inhibition curves, and are shown in Table 1B. From this data it can be seen that:
      • (a) the R(+)-PAI is twice as active as the racemate for inhibition of MAO-B;
      • (b) the R(+)-PAI is 29 times more active for inhibition of MAO-B than MAO-A;
  • (c) the S(−)-PAI is only 1/6,800 as active as the R(+)PAI for inhibition of MAO-B, and shows little or no selectivity between MAO-B and MAO-A.
    TABLE 1A
    IC-50 (nM) VALUES FOR INHIBITION OF
    MAO-A AND MAO-B BY RACEMIC-PAI AND THE
    R(+) AND S(−) ENANTIOMERS THEREOF IN
    RAT BRAIN HOMOGENATE IN VITRO
    IC-50 (nM)
    MAO-A MAO-B
    S(−)PAI R(+)PAI Rac S(−)PAI R(+)PAI Rac
    26000 73 140 17000 2.5 5
  • The results of the same experiments using R(+) and S(−) MPAI (N-methyl-N-propargyl-1-aminoindan) are reported in Table 1B. Each of the enantiomers of MPAI is less selective in MAO-A and MAO-B inhibition than R(+)PAI. Furthermore, R(+)-MPAI is only five times as active as S(−)-MPAI in MAO-B inhibition, in contrast to R(+)-PAI which is about 7000 times as active as S(−)-PAI in this assay.
    TABLE 1B
    IC-50 (nM) VALUES FOR INHIBITION OF MAO-A AND MAO-B BY
    T
    Figure US20060094783A1-20060504-P00899
    R(+) AND S(−) ENANTIOMERS OF MPAI IN RAT
    BRAIN HOMOGENAT
    IN VITRO
    IC-50 (nM)
    MAO-A MAO-B
    Compound: S(−)MPAI R(+)MPAI S(−)MPAI R(+)MPAI
    70 3 50 10
  • Some experiments were also carried out with human cerebr cortical tissues obtained 6 hours post-mortem, and treat as described above. The results of such an experiment a shown in FIG. 3, where R(+)-PAI, S(−)-PAI, and racemic P are as defined herein.
    • EXAMPLE 23 Inhibition of MAO Activity In Vivo: Acute Treatment Experimental Protocol
  • Rats (male Sprague-Dawley-derived) weighing 250±20 g we treated with one of the enantiomers or the racemic form PAI by intraperitoneal injection (ip) or oral gavage (p and decapitated 1 h or 2 h later respectively. Groups three rats were used for each dose level of inhibitor, a MAO activity determined in brain and liver using the gener technique described above. The amount of protein in each incubation was determined using the Folin-Lowry method, a enzyme activity calculated as nmol of substrate metaboli
    Figure US20060094783A1-20060504-P00999
    per hour of incubation for each mg of protein. Activity MAO in tissues from animals treated with inhibitors
    Figure US20060094783A1-20060504-P00999
    expressed as a percentage of the enzyme activity in a gr
    Figure US20060094783A1-20060504-P00999
    of control animals administered vehicle (water for o
    Figure US20060094783A1-20060504-P00999
    administration, 0.9% saline for ip injection) and killed as above.
  • Results
  • None of the dose levels used with the inhibitor drugs produced any-obvious behavioral alteration. The results are depicted in FIGS. 4 to 11. Following i.p. administration, compound R(+)PAI produced 90% inhibition of brain MAO-B. activity at a dose of 0.5 mg/kg. The same dose produced only 20% inhibition of MAO-A activity. By oral administration, the same dose of R(+)PAI produced 80% inhibition of MAO-B with no detectable inhibition of MAO-A. Essentially similar results were seen for inhibition of hepatic MAO, as for brain MAO. The doses producing 50% inhibition of MAO-A and MAO-B (IC-50) were calculated from the inhibition curves, and are shown in Table 2. These data show: (a) that MAO inhibitory activity of R(+)PAI is maintained in vivo in the rat; (b) that selectivity for inhibition of MAO-B, as opposed to MAO-A, by R(+)PAI is maintained in vivo; (c) that the much greater activity of the (+)-enantiomer as opposed to the (−)-enantiomer, is maintained in vivo; (d) that the compounds are effectively absorbed after oral administration; and (e) that the compounds effectively pass the blood-brain barrier, and effectively inhibit brain MAO. The fact that R(+)-PAI was about twice as active as the racemic compound for inhibition of MAO-B is a reflection of the extremely low activity of S(−)-PAI for inhibition of MAO-B.
    TABLE 2
    IC-50 VALUES (mg/kg) FOR INHIBITION OF MAO-A AND MAO-B
    BY R(+)-PAI, S(−)-PAI OR RACEMIC-PAI, IN THE RAT
    FOLLOWING INTRAPERITONEAL (I.P.) INJECTION OR ORAL
    ADMINISTRATION (P.O.)
    IC-50 (mg/kg)
    MAO-A MAO-B
    Compound: S(−)PAI R(+)PAI Rac S(−)PAI R(+)PAI Rac
    I.P. BRAIN >10 1.2 2.5 >10 0.07 0.22
    I.P. LIVER >10 5 5 >10 0.06 0.11
    P.O. BRAIN >10 >5 >5 >10 0.17 0.29
    P.O. LIVER >10 >5 >5 >10 0.05 0.09

    (Rac = Racemic PAI)
    • EXAMPLE 24 Inhibition of MAO Activity In Vivo: Chronic Treatment Experimental Protocol
  • Rats (specifications as in Example 23, 4 animals for each dose level) were treated with R(+)PAI or the racemic mixture at three dose levels (0.05, 0.1 and 0.5mg/kg) by oral administration, one dose daily for 21 days, and decapitated 2 hours after the last dose. The activities of MAO types A and B were determined in brain and liver as described in Example 23.
  • Results
  • A daily dose of 0.1 mg/kg of compound R(+)PAI produced a good degree of selective inhibition, with more than 80% inhibition of brain MAO-B and 20% or less inhibition of brain MAO-A. At the higher dose of 0.5 mg/kg daily, MAO-A was still inhibited by less than 50% (FIGS. 12 and 13). Hepatic MAO showed a similar degree of selective inhibition (FIGS. 14 and 15). Compound R(+)PAI was again more potent than the racemic mixture by a factor of about twofold. In the case of brain MAO, R(+)PAI had a better degree of selectivity for inhibition of MAO-B than did the racemic mixture.
  • These results show that selectivity of MAO-B inhibition can be maintained following chronic treatment with the compounds. As with other irreversible inhibitors, the degree of enzyme inhibition is greater with chronic treatments than that following a single dose of the drug. Compound R(+)PAI shows a better degree of selectivity for inhibition of brain MAO-B than the racemic mixture.
    • EXAMPLE 25 Irreversible Nature of MAO Inhibition Experimental Protocol
  • A single dose of compound R(+)PAI (1 mg/kg) was administered by i.p. injection to groups of 4 rats, and the animals killed 2, 6, 18, 24, 48 and 72 hours later. Activity of MAO-B was determined in whole brain tissues as described hereinabove.
  • Results
  • The results are shown in FIG. 16. Maximal inhibition of MAO-B was attained at 6 hours after injection. MAO activity had only returned to 30% of control activity at 72 hours after injection. This experiment demonstrates the irreversible nature of the MAO inhibition by R(+)PAI.
    • EXAMPLE 26 Potentiation of Tyramine Pressor Effect in Conscious Rats Experimental Protocol
  • Rats were anesthetized with a mixture of pentobarbital (30 mg/kg) and chloral hydrate (120 mg/kg) by intraperitoneal injection. The left carotid artery and jugular vein were cannulated with fine polytene tubing (artery) or fine silicone rubber tubing connected to polyethylene tubing (vein), the distal end of which was brought under the skin to an anchor point behind the neck. The tubing was filled with heparinized saline solution, and plugged with a fine steel rod. The animals were treated with 2. mg chloramphenicol by intramuscular injection and allowed to recover from the operation overnight. The following day, the rats were placed in a high-walled container permitting free movement. The arterial catheter was connected to a pressure transducer via a 100 cm length of saline-filled, fine-bore polyethylene tubing, and the venous catheter connected to a 1 ml syringe via a similar length of tubing, which, together with the syringe, contained a solution of tyramine hydrochloride in saline (1 mg/ml). Following an equilibration period of 30 to 40 minutes, tyramine injections (50 or 100 μg) were given, and blood pressure-responses recorded. An interval of at least 15 minutes was maintained between injections after return of blood pressure to control values. Control pressor responses were established, then one of the drugs was injected intraperitoneally, and tyramine responses were repeated over the next 4 hours. The area under the blood pressure response curve was estimated, and the ratio of this area after treatment to before treatment and to 1 to 3 hours after injection of the compounds, was determined using the average of 3 to 4 values obtained in the control period.
  • Results
  • The results are shown in Table 3. Compound AR(+)PAI at a dose of 1 mg/kg (which causes complete inhibition of MAO-B in brain and liver, and 40 to 50% inhibition of MAO-A in these tissues) caused no significant potentiation of tyramine pressor response. At the higher R(+)PAI dose of 5 mg/kg (which causes more extensive inhibition of MAO-A in brain and periphery), there was a significant potentiation of the tyramine pressor response, which was similar in extent to that produced by the same dose of deprenyl, and less than that produced by clorgyline (at a dose which inhibits hepatic MAO-A activity by over 85%).
    TABLE 3
    POTENTIATION OF TYRAMINE PRESSOR EFFECT IN
    CONSCIOUS RATS BY MAO INHIBITORS
    Ratio Area Under
    Dose No. of rats Pressor Response
    Inhibitor (mg/kg) (n) Curve; After/Before SEM*
    Saline 12 1.25 0.28
    Clorgyline 2 6 10.39 2.13
    (−)Deprenyl 1 2 1.15
    (+)Deprenyl 5 3 2.36 0.16
    R(+)PAI 1 3 1.38 0.7
    R(+)PAI 5 3 3.49 0.98

    *SEM = standard error of the mean
  • From this experiment it can be concluded that compound R(+)PAI causes no potentiation of the tyramine pressor effect at a dose which effectively inhibits MAO-B.
    • EXAMPLE 27 Suppression of MPTP-Induced Dopaminergic Toxicity by R(+)PAI
  • 1-Methyl-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that damages nigrostriatal dopaminergic neurons in several mammalian species, including mice, and produces a Parkinsonian syndrome in humans and primates. A crucial initial step in the mechanism of its neurotoxicity involves conversion of MPTP to its toxic metabolite 1-methyl-4-phenyl pyridinium ion (MPP+). This reaction is catalyzed by the enzyme MAO-B and probably takes place outside of dopaminergic neurons, mainly in glia. It is known that MPTP is both a substrate and an irreversible inhibitor of MAO-B. Pretreatment of experimental animals with MAO-B inhibitors such as deprenyl or pargyline protects against and prevents the MPTP-induced damage to nigrostriatal neurons because the oxidative conversion of MPTP to MPP+ is blocked. The progressive nigrostriatal degeneration in Parkinson's may be due to exposure to environmentally-derived exogenous MPTP-like neurotoxins. In such cases, there is an additional strong indication of initiation of sustained treatment with an MAO-B inhibitor from the very early stages of Parkinson's disease in the hope that it will neutralize the damaging effects of such yet putative MPTP-toxins, and thus arrest or slow down the progression of the illness. A successful MAO-B inhibitor drug is currently judged by its ability to block MPTP-induced damage to nigrostriatal dopaminergic neurons in vivo. The (−) and (+) enantiomers of PAI were therefore tested for their potency in preventing or attenuating the MPTP-induced striatal dopamine depletions in mice.
  • Experimental Protocol
  • Male C57 black mice (20-25 g weight) were (a) injected with MPTP-HCl (30 mg/kg dissolved in distilled water, s.c.), or vehicle alone, or one hour after pretreatment with the (−) or (+) isomers of PAI (2.5 mg/kg, i.p.), or with deprenyl (5 mg/kg, i.p.), and (b) decapitated 5 days later. Brains were removed and corpora striata dissected on an ice-cold glass plate and frozen on dry ice. Striatal tissues were homogenized in 0.1 M perchloric acid, and deproteinized aliguots containing dihydroxybenzylamine as an internal standard were assayed for dopamine and its major metabolite 3,4-dihydroxy-phenylacetic acid (DOPAC) using HPLC with electrochemical detection.
  • Results
  • Table 4 shows the results of this experiment. Treatment with MPTP alone produced marked striatal dopamine (DA) and DOPAC depletions. Treatment with the (−) and (+) enantiomers of PAI or with (−) deprenyl did not affect striatal DA concentrations. Pretreatment with the (−) isomer of PAI did not affect the MPTP-induced DA and DOPAC levels in the striatum. The (+)-isomer of PAI given before MPTP completely abolished the reduction in striatal DA and DOPAC levels produced by the toxin. At a dose of 2.5 mg/kg, (+)PAI was equipotent to (−) deprenyl (5 mg/kg) in its protective effect.
    TABLE 4
    EFFECT OF PRETREATMENT WITH THE (−) AND (+)
    ENANTIOMERS OF THE MAO-B INHIBITOR PAI ON THE
    STRIATAL DA AND DOPAC DEPLETIONS INDUCED BY
    MPTP IN MICE IN VIVO
    DA DOPAC
    (ng/mg protein)
    Control 162.8 ± 7.2 8.4 ± 0.5
    MPTP  53.1 ± 6.2 3.2 ± 0.3
    (−)PAI 174.0 ± 4.8 7.5 ± 0.2
    (−)PAI + MPTP  53.4 ± 6.9 7.0 ± 0.6
    (+)PAI 185.0 ± 6.9 3.3 ± 0.3
    (+)PAI + MPTP  177.8 ± 14.4 6.0 ± 0.3
    (−)Deprenyl 170.6 ± 7.1 5.6 ± 0.3
    (−)Deprenyl + MPTP 197.0 ± 8.0 6.4 ± 0.5
  • Above values for DA and DOPAC expressed as Mean±S.E.M. and number of rats. n=7-11 in each group. These results indicate that the R(+)PAI is an excellent MAO-B inhibitor in vivo, and is of especially great potential for the treatment of Parkinson's disease.
  • While the invention has been described with reference to the aforementioned Examples and the accompanying Tables and Figures, it is not restricted thereto. Various modifications and applications of the invention are possible. For example, (R)-PAI may be combined, in a synergistic way, with α-tocopherol (a vitamin E derivative) for the treatment of Parkinson's disease.
    • EXAMPLE 28 Effect of PAT Enantiomere on Amphetamine Induced Stereotype Behavior in Senescent Rate
  • Amphetamine is known to induce stereotypic behavior (Sulser, F., and Sanders-Bush, E., Ann. Rev. Pharmacol., 11, 209-230 (1971)) by the mobilization of endogenous dopamine. Amphetamine is not metabolized by MAO-B. Inhibition of MAO-B by an effective inhibitor and administration of amphetamine cause release of dopamine which will not undergo degradation by the inhibited MAO-B. Thus, an increase of synaptic dopamine is expected after administration of amphetamine and effective MAO-B inhibitor leading to an increase in stereotype behavior-potentiation of the amphetamine effect. The extent of this behavior is rated in accordance with the number of lateral head movements over a period of 1 minute.
  • Experimental Protocol
  • The test compound was administered at a dose of 0.5 mg/kg/day in drinking water, 24 hours before the infliction of hypoxia (92% nitrogen+8S oxygen for 6 hours). Following that, amphetamine was injected s.c. at a dose of 0.5 mg/kg. 45 minutes later, lateral head movements were counted.
  • Results
  • The results of these experiments are shown in Table 5.
    TABLE 5
    EFFECT OF PAI ISOMERS ON AMPHETAMINE-INDUCED
    STEREOTYPE BEHAVIOR IN SENESCENT RATS (CONTROL
    AND HYPOXIA LESIONED)
    Stereotype
    Group Treatment Behavior Rating
    Control (6) —  87 ± 10
    Control (5) (+)PAI  126 ± 16*
    Control (4) (−)PAI  94 ± 18
    Hypoxia lesioned (5) —  93 ± 12
    Hypoxia lesioned (6) (+)PAI 143 ± 6*

    Numbers in parentheses are numbers of animals tested.

    *P < 0.001 with respect to untreated hypoxia group or untreated control group correspondingly.
  • The results in Table 5 indicate that (+)PAI caused significant potentiation of the amphetamine-induced stereotype behavior in both hypoxia-lesioned and control rats. (−)PAI was totally inactive in this respect. These behavioral in vivo results corroborate previous biochemical findings that (+)PAI is an active inhibitor of MAO-B in the brain while (−)PAI is inactive in this respect.
    • EXAMPLE 29 Effect on R(+)-PAI on the Improvement or Restoration of Memory
  • Newborn rat pups subjected to a brief episode of anoxia and then allowed to resume their growth in a normal way develop a long-lasting impairment of memory (Speiser, et al., Behav. Brain Res., 30, 89-94 (1988)). This memory impairment is expressed as an inferior performance in the passive avoidance test.
  • The effect of R(+)-PAI and S(−)-PAI on the improvement or restoration of memory was investigated in the passive avoidance test. If the drug is effective, it increases the latency of response to enter a dark compartment or chamber where an electroshock has been experienced earlier by the rat being tested. The latency of the maximal response is 300 seconds.
  • Experimental Protocol
  • Young rats were subjected to post-natal anoxia as described in Example 27. R(+)-PAI or S(−)-PAI were administered according to one of the following protocols.
  • Protocol A—Nursing mothers were given a dose of either isomer of 1-1.5 mg/kg/day in drinking water until weaning at 21 days. Following that, the weaned offsprings were directly treated with the same dose for 20 days. Treatment was terminated at 40 days and the test was performed at 60 days, that is 20 days after the last dose of the drug.
  • Protocol B—The dose was reduced to 0.5 mg/kg/day administered to the nursing mother until weaning at 21 days, then directly to the young rats to 60 days at which time the test was performed.
  • Passive Avoidance Test—The apparatus consisted of a lit chamber adjoining a dark chamber and a sliding door separating the two. At training, a rat was placed in the lit chamber for 30 seconds, and then the door was opened. The rat moved to the dark chamber with a latency that was recorded. Upon entry of the rat into the dark compartment, the door was closed and a 0.3 mA foot-shock was delivered for 3 seconds.
  • Retention (memory) after 48 hours was determined by repeating the test and recording the latency to step through from light to darkness to an arbitrary maximum of 300 seconds.
  • Results
  • The results of these experiments are shown in Table 6.
    TABLE 6
    EFFECT OF PAI ISOMERS ON PASSIVE AVOIDANCE
    RESPONSE IN YOUNG RATS (60-DAYS OLD)
    Before After
    Group Treatment Electroshock Electroshock
    PROTOCOL A
    Control — 49 ± 13 201 ± 111
    Control (+)PAI 49 ± 19 220 ± 100(+9%)*
    Control (−)PAI 48 ± 13 192 ± 116
    Anoxia-lesioned — 45 ± 11 183 ± 109
    Anoxia-lesioned (+)PAI 49 ± 10 239 ± 99(19%)*
    Anoxia-lesioned (−)PAI 55 ± 27 179 ± 123
    PROTOCOL B
    Control — 53 ± 20 104 ± 101
    Control (+)PAI 48 ± 11 128 ± 119(+23%)*
    Anoxia-lesioned — 45 ± 8  119 ± 105
    Anoxia-lesioned (+)PAI 52 ± 12 137 ± 126(+15%)*
    Anoxia-lesioned (−)PAI 48 ± 19 112 ± 112

    Figures represent the latency in seconds for entering a dark compartment where an electroshock had been first experienced by the rat tested.

    *The indicated percent increases are with respect to the corresponding anoxia or control groups.
  • The experimental results indicated that (+)PAI but not (−) PAI is effective in improving the memory of anoxia-lesioned and control rats. Drugs active in this test are considered to be potentially useful for treatment of various memory impairment disorders, dementia and especially senile dementia of the Alzheimer's type.
    • EXAMPLE 30 Effect of R(+)-PAI on the Anoxia-Induced Hyperactive Syndrome in Juvenile Rats
  • Rats that had been exposed postnatally to anoxia and then left to grow under normal conditions show increased motor activity in the open field at the age of 10-42 days (Hertshkowitz, et al., Dev. Brain Res., 7, 145-155 (1983)).
  • The effect of R(+)PAI and S(−)PAI on such hyperactive syndrome was investigated.
  • Experimental Protocol
  • Anoxia was performed on rat pups on the first post-natal day. They were placed in a glass chamber and exposed to 100% nitrogen for 25 minutes. They were resuscitated by intermittent massage softly applied to the chest and then returned to their respective mothers. Control rats received the same treatment but with air instead of nitrogen.
  • The R(+)-PAI or S(−)-PAI (0.5 mg/kg/day) was administered to the nursing mothers in drinking water, thereby transferred to the sucklings through milk.
  • Locomotion was measured in 6 fully computerized cages (28×28 cm) by recording the number of crossings over a given period of time. Crossings of grid infrared beams at 4-cm intervals initiated electrical impulses which fed a counter. Recordings of motor activity were made at the ages of 15 and 20 days, over a period of 15 minutes.
  • Results
  • The experimental results are given in Table 7.
    TABLE 7
    EFFECT OF EACH OF THE TWO ENANTIOMERS ON THE
    ANOXIA-INDUCED HYPERACTIVE SYNDROME
    15-day old 20-day old
    Group Treatment rats rats
    Control — 414 ± 192(11) 808 ± 212(12)
    Control (+)PAI 254 ± 149(11) c 719 ± 110(13)
    Anoxia- — 482 ± 119(7) 858 ± 96(9)
    lesioned
    Anoxia- (+)PAI 276 ± 186(15) a 737 ± 150(16) c
    lesioned
    Anoxia- (−)PAI 334 ± 196(5) 778 ± 232(6)
    lesioned

    Numbers in parenthesis are numbers of animals tested.

    —The figures are the numbers of crossings of infrared beam grid in the activity cage over a period of 15 minutes.

    a P < 0.001 compared to anoxia untreated group.

    b P < 0.05 compared to anoxia untreated group.

    c P < 0.05 compared to control group.
  • These results indicate that chronic oral treatment with R(+)-PAI at a dose of 0.5 mg/kg administered to the nursing mother and reaching the milk-fed offspring significantly improved the hyperactive syndrome. Consequently, R(+)-PAI is a potentially useful drug for the treatment of the hyperactive syndrome in children.
    • EXAMPLE 31 Stability Differences Among Ten Salts of PAI
  • Stability is an important factor in the selection of an optimal salt as a therapeutic drug. Different salts may alter the physicochemical and biological characteristics of a drug and can have a dramatic influence on its overall properties. (Berge, S. M., et al., J. Pharm. Sci. 66, 1 (1977); Gould, P. L., Int. J. Pharmaceutics, 33, 201 (1986)).
  • Experimental
  • Synthesis of PAI Salts
  • A solution of an appropriate acid (1 mol-eq.) in 2-propanol was added to a solution of PAI (1 mol-eq.) while stirring in 2-propanol (Ar, BHT). The salt formed was filtered, washed with 2-propanol and ether, and dried under low pressure. Yields were between 70 to 90%. An exception in preparing PAI acetate involved using ether as the solvent.
  • Analytical Methods
  • The chromatographic separations were carried out using a Lichrosphere 60 RP select B 5μ 125×4 mm (Merck) column, an HPLC (Jasco BIP-1) equipped with a L-4200 UV-Vis detector (Merck-Hitachi) set to 210 nm, and a D-2500 chromato-integrator (Merck-Hitachi). The eluent and diluent consisted of 80% distilled water/20% acetonitrile (HPLC grade), and 0.07 M perchloric acid adjusted to pH 2.5 with aqueous ammonia. The flow rate used was 1 ml/min, the appropriate PAI salt solution concentration was 250 μg/ml, and 20 μl of the solution were injected onto the chromatographic system.
  • The melting range was measured with an automatic apparatus (Mettler FP 80) and thermo-gravimetric analysis was performed on a Mettler TA 3000 system at a rate of 10° C./min in the applicable range. Solubility was determined by an appropriate dilution of the supernatant from a saturated PAI salt water solution and measured in a UVIKON 941 (Kontron) UV-Vis spectrophotometer. The salt form (mono- or di-salt) was obtained by elemental analysis using standard equipment for C, H, N and S determination. The pH was measured in a 1% aqueous solution of the PAI salts.
  • Results
  • The characterization of the various salts are summarized in Table 8.
    TABLE 8
    PHYSICOCHEMICAL PROPERTIES OF PAI SALTS
    Melting
    PAI-salt Solubility range Salt
    m.w. pH mg/ml (° C.) % Wt. loss form
    tartarate 5.5  33 176.2-177.3 LT 0.1 di
    492
    mesylate 4.3 635 156.8-157.6 0.1 mono
    267
    maleate 4.0  NLT 1000 87.2-87.8 0.1 mono
    287
    sulphate 3.9 485 159.4-161.1 3.2 di
    440
    chloride 4.2 238 177.0-180.0 LT 0.5 mono
    207
    tosylate 4.4 60-70 129.3-129.9 LT 0.1 mono
    343
    fumarate 3.5  95 125.4-126.2 0.2 mono
    287
    phosphate 7.0 NLT 720 109.5-110.4 n.a. n.a.
    n.a.
    esylate 2.4 NLT 300 n.a. n.a. mono
    279
    acetate 6.1 NLT 720 69.2-69.7 0.4 mono
    231

    n.a. = not available
  • Comparative stability studies were carried out under sets of several accelerating conditions: I) heating at 80° C. for 72, 96 or 144 hours; and II) reflux in isopropanol for 30 hours. The degradation products developed were measured by HPLC and confirmed by TLC. The results are presented in Table 9 with the relative retention time (relative to the PAI peak; RRT) as an area percentage relative to to
    Figure US20060094783A1-20060504-P00999
    integrated peak area.
    TABLE 9
    DEGRADATION PRODUCTS DEVELOPED IN PAI SALTS UNDER
    SHORT TERM CONDITIONS
    Reflux in
    80 C./72 h 80 C./144 h iPrOH/
    Figure US20060094783A1-20060504-P00899
    Salt RRTa %b RRT % RRT %
    sulfate  NDc ND ND ND 0.47 0.22
    0.60 0.72
    phosphate 0.60 0.22 0.60 0.57 0.60 2.62
    0.74 0.21
    1.84 0.20
    1.98 0.73
    chloride ND ND ND ND 2.23 0.71
    mesylate ND ND ND ND 0.60 0.08
    maleate 0.60 0.41 n.a. 0.60 2.17
    1.27 0.50 0.65 1.35
    1.48 0.33 1.29 0.59
    1.81 0.10 1.42 1.30
    3.07 1.44 1.50 0.16
    4.16 0.10 1.83 0.18
    4.84 7.76 1.98 0.23
    4.09 0.65
    acetate 0.44 0.10 n.a. 0.60 6.74
    0.60 2.56 0.74 0.35
    0.73 0.13 1.76 0.33
    1.29 0.71 1.84 0.16
    1.55 1.06 1.99 4.17
    1.75 21.85  3.60 0.27
    1.96 3.33
    2.15 0.08
    2.32 0.15
    2.83 0.15
    3.54 1.82
    esylated ND ND 0.85 0.26 ND ND
    1.96 0.31

    limit of quantitation = 0.08%

    n.a. = not available

    aRelative retention time (relative to the PAI peak).

    bArea percentage relative to total integrated peak area.

    cNo impurities detected.

    dEthyl sulfate salt.
  • The salts were submitted to visual inspection of color an form. The findings are shown in Table 10.
    TABLE 10
    APPEARANCE OF PAI SALTS UNDER DESTRUCTIVE
    CONDITIONS
    reflux in
    Salt 80° C./72 h 80° C./96 h 80° C./144 h iPrOH/30 h
    sulfate off white n.a. off white brown
    powder powder powder
    phosphate brownish n.a. brown brown
    powder powder powder
    chloride white n.a. white off white
    powder powder powder
    mesylate white n.a. white white
    powder powder powder
    maleate brown brown n.a. brown
    melted melted
    esylate brownish n.a. dark brown dark brown
    melted melted melted

    n.a. = not available
  • These studies show that sulphate, esylate and mesylat possess significant advantages relative to the other salt due to good solubility and chemical stability. Of these three salts, mesylate is preferable due to its excellent stability even under destructive conditions.
    • EXAMPLE 32 Reversal of Haloperidol-Induced Catalepsy in Mice
  • Male, ICR mice 25-30 g each, were pretreated with either of the following drugs: Saline, (R)-PAI mesylate, or racemic-PAI mesylate. All drugs were administered i.p. in a volume of 0.2 mL. Two hours later, haloperidol was injected s.c. at a dose of 6 mg/kg in a volume of 0.1-0.2 mL. Motor coordination tests were made at 3 hours after giving haloperidol, that is, 5 hours after administering the presumed protective drugs.
  • Motor coordination tests and rigidity were quantified according to three different parameters: (a) ability to walk the length of a horizontal rod, 80 cm-long; (b) ability to climb down, face down, a vertical rod, 80 cm-long; (c) duration of immobility in an unnatural sitting posture whereby the abdomen of the mouse is pressed against a “wall.” Full performance as in haloperidol-untreated mice is given the score of 4 in each test, or a total of 12 in all tests. Poor performance is given a score from 1 to 3. A key to score ratings is given in Table 9A. The effects of the various agents in antagonizing haloperidol-induced catalepsy are given in Table 11. At three hours after haloperidol, (R)-PAI mesylate conferred protection against haloperidol at 5-15 mg/kg, reaching a peak after effect at 7.5-10 mg/kg (activity score=94% of saline control). Racemic PAI mesylate conferred partial protection in the range of 7.5-15 mg/kg, and was not active at 5 mg/kg. From FIG. 17, it can been seen that the dose-effect profile of either (R)-PAI mesylate or racemic PAI is such that an increase in dose beyond 10 mg/kg entails a decrease in effect, but that the racemic mixture is less potent throughout. This means that racemic PAI mesylate at twice the dose of (R)-PAI mesylate will always be less active than the (R) enantiomer.
    • Reversal of α-MpT-induced Hypokinesia in Rats
  • The drug α-MpT is assumed to inhibit the formation of L-DOPA from tyrosine, and consequently the formation of dopamine itself. Lack of CNS dopamine is expressed as hypoactivity. Six month-old male Wistar rats (from Harlan Orkack, UK) were pretreated with saline, (R)-PAI Mesylate or Rac PAI Mesylate, at the indicated doses. Two hours later they received i.p. α-MpT at a dose of 100 mg/kg in 0.3-0.5 mL. Controls received saline. Following this, motor activity was recorded in a computerized activity cage for the duration of 10 hours. The results are given in Table 12 and FIG. 18. At 2 mg/kg, (R)-PAI Mesylate restored the level of activity to about 90% of the saline-treated rats, but Rac PAI Mesylate was not active. In either case, the profile of the dose-effect curve was bell-shaped, suggesting a decrease in effect with an increase in dose beyond a peak of 2-5 mg/kg. At 5 mg/kg Rac PAI Mesylate could not elicit a level of activity comparable to that of (R)-PAI Mesylate at 2 mg/kg.
  • From these measurements, (R)-PAI Mesylate and Rac PAI-Mesylate do not share a similar pattern of activity in the restoration of normokinesia in haloperidol-treated mice and α-Mpt-treated rats. A all doses studied, (R)-PAI Mesylate is always more potent that Rac PAI Mesylate at the corresponding dose. Also, peak activity of Rac PAI Mesylate is always lower than peak activity of (R)-PAI Mesylate. Thus, Rac PAI Mesylate at a given dose is always less effective than (R)-PAI Mesylate at half the same dose. Doubling the dose of Rac PAI Mesylate with respect to (R)-PAI Mesylate does not produce an effect equivalent to that of (R)-PAI Mesylate.
  • Pharmacologically, Rac PAI Mesylate cannot be considered as consisting of 50% active ingredient which is (R)-PAI Mesylate and 50% inert material as diluent. The presence of (S)-PAI in Rac PAI Mesylate has an adverse effect on the activity of (R)-PAI, resulting in a more than two-fold decrease in potency. The decrease may be due to a direct adverse effect of (S)-PAI on behavioral parameters.
    TABLE 11
    REVERSAL OF HALOPERIDOL-INDUCED CATALEPSY IN MICE
    WITH (R)-PAI MESYLATE AND RACEMIC MESYLATE
    Mice received each of the test drugs i.p. at the indicated
    doses. Two hours later they received haloperidol as
    described in the text. The doses shown are for the free
    base.
    (R)-PAI Mesylate Rac PAI Mesylate
    Dose, % of % of
    mg/kg Score + SE n control Score + SE n control
    1.8 7.2 ± 1    6 60 7.0 ± 0.6   6 59
    3.0 6.4 ± 0.5  6 60 5.9 ± 0.7   6 49
    5.0 8.7 ± 0.9*  6 73 6.4 ± 0.4   6 53
    7.5 11.0 ± 0.4*** 5 92 9.4 ± 0.8++  6 78
    10 11.3 ± 0.3*** 6 94 9.2 ± 0.6*** 6 77
    15 10.8 ± 0.5*** 5 90 8.8 ± 0.8*  6 73
    Control 12 ± 0   12 100
    saline
    Haloperidol 6.6 ± 0.3  16 59
    alone

    Statistical significance with respect to haloperidol alone:

    *p ≦ 0.05;

    **p ≦ 0.01;

    ***p ≦ 0.001 by the Student's “t” test.

    The scores for (R)-PAI are significantly different from those of racemic PAI at 5 mg/kg, p ≦ 0.05; at 10 mg/kg, p ≦ 0.01; and at 15 mg/kg, p ≦ 0.05.
  • TABLE 11A
    KEY TO SCORE RATING OF HALOPERIDOL-INDUCED
    CATALEPSY IN MICE AND ITS REVERSAL BY VARIOUS
    AGENTS
    Vertical Rod:
    Unable to grasp rod with limbs 1
    Able to grasp but slips down 2
    Able to grasp, partly slips, partly climbs down 3
    Able to grasp, climbs down using all limbs 4
    Horizontal Rod:
    Unable to grasp, falls off rod 1
    Able to grasp, unable to walk on rod more than 2 paces 2
    Able to grasp, walks half-length of rod 3
    Able to grasp, walks full length of rod 4
    Immobility Sitting Against Wall:
    Immobility >5 min 1
    Immobility 3-5 min 2
    Immobility 1-3 min 3
    Immobility 0.1 min 4
  • Fractional scores are assigned, such as 2.5, when behavior falls between two categories, as between 2 and 3.
    TABLE 12
    RESTORATION OF MOTOR ACTIVITY IN RATS TREATED WITH
    α-METHYL-p-TYROSINE (α-MpT) AT 100 mg/kg i.p.
    Rats received the test drugs i.p. at the indicated doses.
    After two hours they received α-MpT and were immediately
    placed in activity cages. Total motor activity was
    automatically recorded for 10 hours, as described in the
    text.
    (R)-PAI Mesylate Rac PAI Mesylate
    Dose, % of % of
    mg/kg Score + SE n control Score + SE n control
    2 14,132** ± 1457  7 89  9,035 ± 829 6 57
    5  12,893* ± 1,869 7 81 10,926* ± 820 8 69
    7.5   6,679 ± 414   4 42  9,698 ± 557 4 61
    Control  15,862 ± 1,424 5 100
    saline
    α-Mpt 8,108*** ± 810   6 51
    alone

    Statistical significance by the Student's “t”,

    *p ≦ 0.01;

    ***p ≦ 0.001 for Test drugs+ α-Mpt versus α-MpT alone α-Mpt alone versus control saline

    The scores of (R)-PAI versus racemic PAI are significantly different at 2 mg/kg, p ≦ 0.01.
    • EXAMPLE 33 The Effects of (R)-PAI Mesylate Following Closed Head Injury in Rats
  • Methods
  • 1. Induction of Trauma
  • Head trauma was induced in male rats under ether anesthesia by a well calibrated weight-drop device that falls over the exposed skull, covering the left cerebral hemisphere, 1-2 mm lateral to the midline, in the midcoronal plane.
  • 2. Evaluation of Motor Function
  • One hour after induction of trauma, the rats were tested by a set of criteria which evaluated their neurologic outcome (the criteria described by Shohami, et al., J. Neurotrauma, 10, 113 (1993)). These criteria, referred to as the Neurological Severity Score (NSS), consist of a series of reflexes and motor functions. Points are given based on deficits in these criteria. At 24 h the rats were re-evaluated.
  • 3. Evaluation of Brain Edema
  • The brains were removed after the second evaluation of motor function (24 h). A piece of tissue (−20 mg) was weighed to yield-wet weight (WW). After drying in a desiccator oven for 24 h at 95° C., it was reweighed to yield dry weight (DW). Water percentage in the tissue was calculated as (WW-DW)×100/WW.
  • 4. Drug Treatment
  • (R)-PAI Mesylate was dissolved in water. The rats were injected intraperitoneally at a dose of 0.1 mg/kg, 0, 4, 8 and 12 h after induction of head trauma. Control rats were treated with water at the same times.
  • Results
  • The NSS, which measures the “clinical” status of the rats, was almost identical in the treated and nontreated groups at 1 hour after the head injury, but significantly lower at 24 hours in the (R)-PAI mesylate-treated rats (Table 13). These results indicate that PAI mesylate is effective in improving motor function recovery following closed head injury in rats.
  • At 24 hours after trauma, a major edema was found in the hemisphere (85.4% water in the brain of control rats vs. 78.5% in undamaged brain tissue). PAI mesylate was effective in reducing edema as verified by its effect on the percent of water.
  • In conclusion, the results reported herein demonstrate that (R)-PAI mesylate has neuroprotective properties in a model intended to mimic human nerve injury and to induce trauma to a closed skull.
    TABLE 13
    NSS Δ NSS % H 20
    1 h 24 h (1 h-24 h) in the brain
    control 15.6 12.3 4.3 ± 0.5  85.4 ± 0.4 
    (n = 6)
    (R)-PAI 16.7 10.2 6.5 ± 0.7* 82.1 ± 0.6**
    Mesylate
    (n = 6)

    *P < 0.05 (Mann Whitney U-test)

    **P < 0.005 (t-test)
    • EXAMPLE 34 Effects of PAS Mesylate on Prevention of NMDA Induced Cell Death of Cerebellum Cell Cultures Results of In Vitro Assays
  • Procedures: cultures of mechanically dissociated neonatal rat cerebellum. The cerebella are dissected aseptically from 6 or 7-day-old rat pups and placed in a 15 ml sterile plastic conic tube containing 3 ml of enriched medium (the medium is made up of Dulbecco's modified Eagle's medium (DMEM) with high glucose concentration (1 g/l), 2 mM (v/v) L-glutamine, antibiotic antimitotic mixture, and enriched with 15% (v/v) heat-inactivated fetal calf serum). The cerebella are then dissociated after 20-25 passages through a sterile 13 gauge, 10 cm long stainless steel needle attached to a 5 ml syringe with an inserted 45 μm pore size nylon sieve. The dissociated cells are centrifuged at 200 g for 5 minutes, the supernatant discarded and the cells resuspended in enriched medium. The cell viability is determined by the trypan blue exclusion test. The cells are then plated at a density of 200/mm2 on poly-L-lysine-coated surfaces (Poly-L-lysine-coated glass coverslips are prepared at least 1 hour before plating, by immersing in a sterile distilled water solution containing 15 μg/ml poly-L-lysine, and just before use, washing with sterile water and drying), covered with enriched medium, and incubated at 37° C. in an atmosphere of 5% CO2 in air and 100% humidity. After 4 days in culture, the media are replaced with media containing the desired test compounds. Experiments are done in duplicate and repeated 2 or 3 times. After determining the test compound toxic dose-response, four groups are compared: (I) control (enriched medium alone), (II) test compound (one subgroup for each concentration (2 concentrations are tested)), (III) N-methyl-D-aspartate (NMDA, exposure to a concentration of 1 mM for 3 h) as the cytotoxic challenge, (IV) test compound plus NMDA (one subgrcup for each of the 2 concentrations of test compounds), (V) control group to test the effect of solvent (in which the test compound is dissolved), and (VI) an additional “positive control” group of spermine (0.01 μM dissolved in culture medium) plus NMDA. Nerve cell survival is evaluated by phase contrast microscopy and trypan blue staining after 24 h.
  • Results
  • It is well established that glutamic acid (Glu) possesses neurotoxic properties which are expressed in several neurological disorders including epilepsy and stroke, and most likely also in brain neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and traumatic brain injury. The neurotoxic effects of Glu are mediated by membrane bound Glu receptors such as N-methyl-D-asparate (NMDA) receptors.
  • The results, as shown in Table 14, demonstrate that 10 μM of (R)-PAI mesylate increased the survival of cerebellum cells by 27 percent following 1 μM NMDA exposure. These in vitro results support the in vivo effects of (R)-PAI mesylate presented in Examples 33 and 35, indicating that this drug has neuroprotective properties against neurotoxic concentration of NMDA.
    TABLE 14
    NEUROPROTECTIVE EFFECT OF (R)-PAI MESYLATE ON
    PREVENTION OF NMDA-INDUCED CELL DEATH OF
    CEREBELLUM CELLS
    Experimental
    Group Surviving Cells Percent Protection
    Cerebellar Cultures
    (Toxicity TD25 = 30 μM; TD50 = 85 μM; TD100 = 320 μM)
    Control 100
    Solvent 97
    NMDA 10
    Solvent + NMDA 10 0
    Compound + NMDA:
    1) 0.01 μM + NMDA 12 2
    2) 1.00 μM + NMDA 22 12
    3) 10.00 μM + NMDA 37 27
    Spermine + NMDA 75 65
  • Values, expressed as the percent of untreated controls, represent the average of 2 experiments run in duplicate for culture experiments, and the mean±SEM of 4 animals for ischemia. The percent protection value is the effect of the test compound after subtraction of the solvent effect.
    • EXAMPLE 35 Effects of (R)-PAI Mesylate After Traded Crush of the Rat Optic Nerve
  • Neuroprotective effects of (R)-PAI Mesylate were determined for application immediately after crush injury of the optic nerve in the adult rat. Short-term effects were measured metabolically, and long-term effects electrophysiologically.
  • Methods
  • 1. Metabolic Measurements
  • a) General. The method is described by Yoles, et al., Investigative Ophthalmology & Visual Science, 3, 3586-91 (1992). At short terms, metabolic measurements were monitored in terms of the mitochondrial NADH/NAD ratio, which depends on the activity of the electron transport system, and thus indicate levels of energy production. Changes in ability of the nerve to produce energy as a consequence of injury were determined by comparing NADH levels in response to artificial transient anoxic insult before and after the injury.
  • b) Surface fluorometry—reflectometry. Monitoring of the intramitochondrial NADH redox state is based on the fact that NADH, unlike the oxidized form NAD+, fluoresces when illuminated at 450 nm. A flexible Y-shaped bundle of optic fibers (light guide) was used to transmit the light to and from the optic nerve. The light emitted from the nerve was measured at two wavelengths: 360 nm (reflected light) and 450 nm (fluorescent light). Changes in the reflected light were correlated with changes in tissue absorption caused by hemodynamic effects and with movements of the optic nerve secondary to alterations in arterial blood pressure and nerve volume. The fluorescence measurements were found to be adequately corrected for NADH redox state measurements by subtraction of the reflected light (366 nm) from the fluorescent light (1:1 ratio) to obtain the corrected fluorescence signal.
  • c) Animal preparation. Animal utilization was in accord with the ARVO Resolution on the use of animals in research. Male Sprague-Dawley (SPD) rats weighing 300-400 g were anesthetized with sodium pentobarbitone (50 mg/kg intraperitoneally). With the animal's head held in place by a head holder, a lateral canthotomy was performed under a binocular operating microscope and the conjuctiva was incised lateral to the cornea. After separation of the retractor bulbi muscles, the optic nerve was identified and a length of 3-3.5 mm was exposed near the eyeball by blunt dissection. The dura was left intact and care was taken not to injure the nerve. A special light-guide holder was implanted around the optic nerve in such a way that the light guide was located on the surface of the optic nerve 1 mm distal to the injury site. Animals, while still anesthetized, were allowed to recover for 30 minutes from the surgical procedures and were then exposed to anoxic conditions. An anoxic state was achieved by having the rat breathe in an atmosphere of 100% nitrogen for 2 minutes; after which time it was returned to air. In order to evaluate the metabolic activity of the optic nerve, the relative changes in reflected and fluorescent light intensities in response to anoxia were measured before and after crush injury.
  • d) Experimental protocol for crush injury and metabolic measurements. With the aid of calibrated cross-section forceps, a moderate crush injury was inflicted on the nerve between the eye and the light guide holder at a pressure corresponding to 120 g for 30 sec. Immediately after injury, animals received intraperitoneal injections of water with and without (R)-PAI Mesylate (2 mg/kg). To assess the activity of the energy production system, NADH response to 2 minutes of anoxia was measured in all animals prior to injury, 30 minutes after injury, and thereafter at hourly intervals up to 4 hours (see FIG. 19).
  • 2. Electrophysiological Measurements. This method is described by Assia, et al., Brain Res., 476, 205-212 (1989). Animal preparation and optic nerve injury were preferred as in the metabolic studies. Immediately after injury, animals received a single injection of water with or without (R)-PAI Mesylate (0.5 mg/kg). Fourteen days after injury and treatment, the optic nerves were excised and measured electrophysiologically. Prior to removal of optic nerves for electrophysiological measurement, the rats were deeply anesthetized with 70 mg/kg pentobarbitone. The skin was removed from the skull and the optic nerves were detached from the eyeballs. Subtotal decapitation was performed and the skull was opened with a rongeur. The cerebrum was displaced laterally, exposing the intracranial portion of the optic nerve. Dissection was at the level of the nerve, which was transferred to vials containing fresh salt solution consisting of NaCl (126 mM), KCl (3 mM), NaH2PO4 (1.25 mM), NaHCO3 (26 mM), MgSO4 (2 mM), CaCl2 (2 mM), and D-glucose (10 mM), and aerated with 95% O2 and 5% CO2 at room temperature. The nerves were kept in this solution, in which electrical activity remained stable for at least 3-4 hours. After 0.5 hours of recovery at room temperature, electrophysiological recordings were obtained from the nerve distal to the crush lesion. The nerve ends were then connected to two suction Ag—AgCl electrodes immersed in a bathing solution at 37° C. A stimulating pulse was applied through the electrode at the proximal end and the action potential was recorded by the distal electrode. A Grass SD9 stimulator was used for supramaximal electrical stimulation (0.5 pps). The measured signal was transmitted to a Medelec PA36 preamplifier and then to an electromyograph (Medelec MS7, AA7T amplifier). The solution, stimulator and amplifier had a common ground. The maximum amplitude of eight averaged compound action potentials (CAPs) was recorded and photographed with a Polaroid camera. The CAP values measured in contralateral uninjured nerves served as a reference.
  • Results
  • The results demonstrate that (R)-PAI Mesylate applied immediately after optic nerve injury blocked the injury-induced reduction in energy production. (R)-PAI Mesylate also has a long-term effect measured by electrophysiological monitoring.
  • The CAP (compound action potentials) amplitude is directly correlated with the number of conducting fibers in the tested segment of the nerve.
  • (R)-PAI Mesylate significantly attenuated the injury-induced loss of activity in the distal segment of the injured nerve, indicating that (R)-PAI Mesylate is a neuroprotective agent or at least slows down degeneration.
    TABLE 15
    Electrophysiological Measurements
    CAP amplitude (μV)
    Group (Mean ± Std. Error.)
    Vehicle 441 ± 95 
    N = 13
    (R)-PAI 2104 ± 313*
    Mesylate
    N = 7
    • EXAMPLE 36 Comparison of Anticonvulsive Properties of R-PAT and S-PAI Salts
  • Both (R)-PAI and (S)-PAI HCl salts have significant anticonvulsant activities. In mice (i.p. administration) in the maximal electroshock test (MES test), (S)-PAI HCl has greater anticonvulsant activity (ED50=57 mg/kg) than (R)-PAI HCl (ED50=79 mg/kg). Analogous results were observed in rats (p.o. administration). Four out of four rats were protected from seizures in the MES test when 50 mg/kg of (S)-PAI HCl was administered, whereas three out of four mice were protected after the same dose of (R)-PAI HCl. With respect to efficacy for Parkinson's disease, the enhanced anticonvulsant activity is a detrimental side effect. The same trend occurs with the mesylate salts. (S)-PAI Mesylate has greater anticonvulsant activity than (R)-PAI Mesylate in the MES test. At doses of 100 mg/kg, (S)-PAI Mesylate protected three out of three mice, whereas only one out of three mice was protected with (R)-PAI Mesylate.
  • The MES test is a classical model to indicate efficacy for partial and generalized seizures in humans. The agents' mechanism of action is via their ability to prevent the spread of seizures. Some agents, however, that prevent seizure spread have the side effect of lowering seizure threshold. These agents therefore have both proconvulsive and anticonvulsive side effects.
  • Results herein show that (S)-PAI Mesylate has proconvulsive activity. In the Timed Intravenous Infusion of Metrazol test, 141 mg/kg of (S)-PAI Mesylate reduces the time, and therefore the amount of Metrazol, required to induce the appearance of both the first focal seizure and the onset of clonus. Other agents that are classically used for partial and generalized seizures, such as phenytoin and carbamazepine, do not show this effect. (H. J. Kupferberg. Epilepsia, 30, s51-s56 (1989)). Likewise, (S)-PAI Mesylate showed a significantly higher acute neurotoxicity than (R)-PAI Mesylate. At 300 mg/kg, (R)-PAI Mesylate did not show any neurotoxicity with mice in the rotorod ataxia test. With (S)-PAI Mesylate, four out of four mice showed neurotoxicity and spasticity.
  • Methods
  • TD50 (Median Toxic Dose). This test measures neurological deficits by the rotorod ataxia test. A mouse is placed on a knurled rod rotating at 6 rpm. It is then determined whether a mouse has the ability to maintain its equilibrium and stay on the rod for one minute in each of three trials.
  • Timed Intravenous Infusion of Metrazol Test. This test measures the minimal seizure threshold of each animal. Metrazol is infused at 0.185 mg/ml into the tail veins of mice. The time is then recorded (sec) from the start of infusion until the appearance of the first twitch (first focal seizure) and onset of clonus (clonic seizure). Proconvulsants require less Metrazol to produce these symptoms and therefore show endpoints at a shorter period of time.
    • EXAMPLE 37 Peripheral Effects of (R)-PAI and (S)-PAI on the Contractility of Intestinal Smooth Muscle Preparations
  • Peripheral effects of the hydrochloride salts of the enantiomers of PAI were determined in isolated rabbit or guinea-pig small intestine. These observations provide useful information on their relative peripheral side effects in humans. The first point of contact of the subject with an orally administered drug is the gastrointestinal tract where concentrations of the drug are much higher than after absorption and distribution. In the case of PAI hydrochloride (Mw=208), a 10 mg oral dose contained in a liquid volume of about 100 ml would be equivalent to a concentration of about 0.5 mM. In contrast, the therapeutic plasma concentration of (R)-PAI hydrochloride is in the nanomolar range.
  • The effect of the enantiomers of PAI in the isolated rabbit jejunum and the guinea-pig ileum were determined so as to find out whether the intake of (S)-PAI together with (R)-PAI (as found in racemic PAI) would produce side effects absent in the administration of pure (R)-PAI. (R)-PAI is the preferred enantiomer for the inhibition of MAO-B in the brain, in view of its potency and high selectivity toward! this form of the enzyme. (S)-PAI is much less potent that (R)-PAI in this respect and is also not selective toward MAO-B. In principle, its presence in PAI racemate might be tolerated or overlooked provided (S)-PAI is inert at the recommended doses of (R)-PAI. The results provided in Tables 16-19 show that (S)-PAI is not an inert substance. On the contrary, in the guinea-pig ileum, it is a more potent relaxant than (R)-PAI. Hence its peripheral effects cannot be discounted as negligible. These data show that there would be fewer peripheral side effects in the administration of pure (R)-PAI than in the administration of racemic PAI containing an equivalent dose of (R)-PAI.
    TABLE 16
    TYRAMINE POTENTIATION BY EACH OF THE TWO
    ENANTIOMERS OF PAI HCl IN RATE JEJUNUM
    PREPARATION
    A stretch of rabbit jejunum, mounted in an organ bath,
    displays rhythmic contractions that are inhibited by
    norepinephrine but not by tyramine. If however the jejunum
    is pretreated with a monoamine oxidase inhibitor such as
    PAI, then tyramine causes relaxation of the spontaneous
    contractions. The extent of relaxation can be correlated
    with the relative potency of the inhibitor.
    Percent
    Drug and concentration (μM) relaxation
    Tyramine alone 40 0
    Norepiniphrine 0.002 100
    (R)PAI alone 0.2-4.0 0
    (S)PAI alone 0.2-4.0 0
    Tyramine 40
    after (R)PAI 0.2 67
    2 88
    40 85-90
    after (S)PAI 0.2 0
    2 35
    40 33-50

    Results
  • (S)-PAI is much less potent than (R)-PAI as an inhibitor of brain MAO-B. Therefore, (S)-PAI is not a useful agent for the prevention of brain dopamine degradation, but can potentiate the tyramine-evoked release of norepinephrine in the small intestine. Its activity in the small intestine is an undesirable side effect as it is expected to increase the absorption and action of undegraded tyramine. Thus, (S)-PAI is not an inert substance when used together with (R)-PAI as found in racemic PAI.
    TABLE 17
    ANTAGONISM OF BETHANECHOL-INDUCED CONTRACTIONS
    OF THE GUINEA PIG ILEUM PREPARATION IN THE PRESENCE
    OF 400 μM OF EACH OF THE TWO ENANTIOMERS OF PAI HCl
    A stretch of guinea-pig ileum mounted in a physiological
    solution in an organ bath contracts dose-dependently when
    treated with bethanechol which is an enzymatically stable
    analog of the natural gastrointestinal neurotransmitter
    acetylcholine. These contractions are attenuated in the
    presence of PAI. The data are expressed in gram-tension.
    gram-tension
    Bathenechol (μM) control (R)PAI control (S)PAI)
    0.8 0.5 0.2 0.6 0
    2 1.5 0.3 2.0 0
    4 2.2 0.7 3.0 0
    8 4.0 1.0 3.8 0.6
    20 5.6 2.0 3.8 1.2
    40 6.2 2.8 3.8 1.7
    80 6.2 3.1 3.8 2.6
    200 6.2 4.3 3.8 2.6

    Results
  • (S)-PAI is almost inactive as a MAO-B inhibitor with respect to (R)-PAI, and hence is not effective in preventing the degradation of brain dopamine. However, it is more effective than R(PAI) in the prevention of the bethanechol-induced contraction of the small intestine. Thus (S)-PAI is not an inert substance when used with R(PAI) as found in racemic PAI.
    TABLE 18
    ANTAGONISM OF THE HISTAMINE-INDUCED CONTRACTIONS
    OF THE GUINEA-PIG ILEUM PREPARATION BY EACH OF THE
    TWO ENANTIOMERS OF PAI HCl
    A fixed dose of histamine (40 nM) causes a sustaine
    Figure US20060094783A1-20060504-P00899
    contraction of a stretch of guinea-pig ileum mounted i
    Figure US20060094783A1-20060504-P00899
    physiological solution in an organ bath. Incrementa
    Figure US20060094783A1-20060504-P00899
    addition of each of the two enantiomers of PAI HCl causes
    dose-dependent relaxation of the muscle. Results a
    Figure US20060094783A1-20060504-P00899
    expressed as percent relaxation with respect to the base
    line before addition of histamine, which is taken as 10
    Figure US20060094783A1-20060504-P00899
    relaxation.
    PAI concentration Percent relaxation
    μM (R)PAI (S)PAI
    2 0 11
    4 0 15
    10 0 30
    20 20
    30 31 33
    40 37 36
    100 81 71
    200 90
    300 92
    400 100 98
    700 100
    1000 100

    Results
  • (S)-PAI is inactive with respect to (R)-PAI as a MA inhibitor in the brain, and hence useless for preventing degradation of brain dopamine, but is more active than (R) isomer in causing relaxation of intestinal smo muscle. Thus, (S)-PAI is not an inert substance when taken together with the (R)isomer as found in racemic PAI.
    TABLE 19
    ANTAGONISM OF THE BETHANECHOL-INDUCED
    CONTRACTIONS OF THE GUINEA-PIG ILEUM
    PREPARATION BY EACH OF THE TWO
    ENANTIOMERS OF PAI HCl
    A fixed dose of bethanechol (0.8 μM) causes a sustained
    contraction of a stretch of guinea-pig ileum mounted in
    physiological solution in an organ bath. Incremental
    addition of each of the two enantiomers of PAI HCl causes a
    dose-dependent relaxation of the preparation. Results are
    expressed as percent relaxation with respect to the baseline
    before addition of histamine, which is taken as 100%
    relaxation.
    PAI concentration Percent relaxation
    μM (R)PAI (S)PAI
    20 25 40-50
    60 25-50 60-70
    100 50-70 100
    300 100 100

    Results
  • (S)-PAI is inactive with respect to (R)-PAI as a MAO-B inhibitor in the brain, and hence useless for the prevention of the degradation of brain dopamine, but is more active than the (R) isomer in causing relaxation of intestinal smooth muscle. Thus, (S)-PAI is not an inert substance when taken together with the (R) isomer as found in racemic PAI.
    • EXAMPLE 38 Some Effects of [R](+)PAI Mesylate in Middle Cerebral Artery Occlusion in the Rat as a Model for Stroke
  • Methods
  • 1.1. Middle cerebral artery occlusion (MCAO) in the rat. A modification of the procedure described by Tamura et al (1981) was used. Male Wistar rats (Olac England-Jerusalem) 300-400 g each were anesthetized with a solution of Equitesine administered i.p. at a dose of 3 mL/kg. Equitesine consists of 13.5 mL sodium pentothal solution (60 mg/mL), 3.5 g chloral hydrate, 1.75 g MgSO4, 33 mL propylene glycol, 8.3 mL absolute alcohol made up to 83 mL with distilled water. Surgery was performed with the use of a high magnification operating microscope, model SMZ-2B, type 102 (Nikon, Japan). In order to expose the left middle cerebral artery, a cut was made in the temporal muscle. The tip of the coronoid process of mandible was excised as well and removed with a fine rongeur. Craniectomy was made with a dental drill at the junction between the median wall and the roof of the inferotemporal fossa. The dura matter was opened carefully using a 27 gauge needle. The MCA was permanently occluded by microbipolar coagulation at low power setting, beginning 2-3 mm medial to the olfactory tract between its cortical branch to the rhinal cortex and the laterate striate arteries.
  • After coagulation, the MCA was severed with microscissors and divided to ensure complete occlusion. Following this, the temporalis muscle was sutured and laid over the craniectomy site. The skin was closed with a running 3-0 silk suture. A shad craniectomy operation was performed on a parallel group of rats, but without cauterization of the MCA. During the entire surgical operation (20-25 min) in either group, body temperature was maintained at 37 to 38° C. by means of a body-temperature regulator (Kyoristsu, Japan) consisting of a self-regulating heating pad connected to a rectal thermistor. At 24 hours post surgery a neurological score was taken in order to assess the severity of the injury in the drug-treated rats with respect to their untreated controls. At 48 hours, the animals were anesthetized with Equitesine and the severity of the injury was visualized by an MRI procedure. The volume of brain tissue incurring damage following ischemia was determined.
  • 1.2. Drug Administration
  • [R](+)PAI Mesylate was administered as an i.p. injection in 0.3-0.4 mL distilled water, according to the following schedule:
  • 1 mg/kg immediately after surgery.
  • 0.5 mg/kg 2 hours after surgery
  • 1 mg/kg 20-24 hours after surgery
  • 1.3. MRI Scan of Ischaemic Brain Lesion
  • All experiments were performed using a 4.7T BIOSPEC system (BRUKER) (See T. Back, et al., “Diffusion Nuclear Magnetic Resnonance Imaging in Experimental Stroke: Correlation with Cerebral Metabolites,” Stroke (February 1954) 25: 494-500). Forty-eight hours after MCAO or sham operation, every animal was subjected to a fast multislices T1 weighted imaging (TR/TE), (500/25) for positioning. Then multislices T2-weighted images (3000/80) were acquired (5 contiguous slices, 3 mm thick).
  • The size and severity of the infarcted area was estimated using the hyperintensity observed in the T2 weighted MRI at 48 hours post-occlusion or post sham-operation. The following MRI parameters were determined for each group of rats:
  • c. Ischemic area (in m2)
  • d. Area of the ischemic hemisphere (in mm2)
  • e. Area of the unaffected hemisphere (in mm2)
  • The use of contiguous slices allows the conversion-of area units into volume units by simply multiplying the area value by the slice thickness
  • 1.4. Neurological Score
  • The neurological score consists of the sum total of a series of ratings assigned to the performance of specific locomotor activities in a given rat. The scale runs from 0 (fully normal rats) to 13 (fully incapacitated rats). Most parameters are rated as either 0 (normal), or 1 (incapacitated); others are graded. The following tests were used in the present study:
  • General observational tests: hypoactivity; sedation; piloerection
  • Motor reflex. Rats were lifted by the tail about 15 cm above the floor. Normal rats assume a posture in which they extend both forelimbs towards the floor and spread the hind limbs to the sides in a trapeze-like manner. MCAO when severe causes consistent flexion of the contralateral limb.
  • Motor ability. This is seen as the ability to grasp a rod 1 cm in diameter by the contralateral limb for 5-15 sec when the rat is left hanging on the rod through the arm pit.
  • Motor coordination. Normal rats are able to walk up and down a beam 5 cm wide placed at a moderate slant. Failure to walk the beam in either direction reveals some motor incoordination, lack of balance and limb weakness.
  • Gait. Ability to restore normal position to either hind contralateral limb when intentionally displaced while on a narrow beam.
  • Balance. Ability to grasp and balance on a narrow beam 2 cm wide.
  • Locomotor activity. Total movements over a period of 15 min in an automated activity cage.
  • Ratings assigned to each of the above parameters are given in Table 20.
    TABLE 20
    Neurological scores assigned to each of 10
    parameters of posture and locomotion
    Parameter Score
    a. Activity in the home cage normal = 0
    hypoactive = 1
    b. Sedation none = 0
    marked = 1
    c. Piloeretion none = 0
    marked = 1
    d. Extension of contralateral good = 0
    forelimb towards floor when flexed limb = 1
    lifted by tail
    e. Spread of contralateral hind good = 0
    limb when lifted by tail flexed limb = 1
    (trapezoid posture)
    f. Grasp rod with contralateral limb good = 0 poor = 1
    f or 5-15 sec. when suspended by
    the armpit
    g. Walk on beam 5-cm wide good = 0 poor = 1
    h. Restoration of contralateral good = 0
    hind and or fore limb to original poor = 1 (one limb)
    position when intentionally 2 (two limbs)
    displaced
    i. Grasping and balance on beam good = 0 poor = 1
    2-cm wide
    j. Motor activity with respect to ≦25% of control 3
    control (for 15 min in an automated 26-50% of control 2
    activity cage 51-75% of control 1
    76-100% of control 0

    2. Results
    2.1. Infarct Size
  • The results of the MRI study are summarized in Table 21 and FIG. 20. The infarct size was significantly smaller in [R](+)PAI Mesylate-treated rats (n=9) than in untreated rats (n=10). In the former, the infarct size was about 60% of that in the untreated animals.
    TABLE 21
    Ischaemic brain lesion evaluation by MRI T2-SCAN - 48]
    following MCA-Occlusion and [R](+)PAI Mesylate treatment
    Wistar Rats.
    MCA-O + [R](+)
    MCA-O PAI Mesylate*
    Infarct size Infarct size
    Animal No. (mm3) Animal No. (mm3)
     1 252 1 94.4
     2 272 2 139
     3 314 3 240
     4 273 4 137
     5 201 5 137
     6 221 6 174
     7 358 7 164
     8 265 8 171
     9 341 9 215
    10 236
    MEAN ± SD 273.3 ± 50.9 MEAN ± SD 163.5 ± 43.9
    t = 5.0475
    f = 17
    p < 0.001
    [R](+)PAI Mesylate reduces infarct size by 40% significantly
    *[R](+)PAI Mesylate administered:
    Time after MCA-Occlusion:
    0 1.0 mg/kg ip;
    2 hrs 0.5 mg/kg ip;
    24 hrs 1.0 mg/kg ip.

    2.2. Neurological Score
  • The neurological score in five [R](+)PAI Mesylate treated rats and six untreated rats were determined by a blinded observer. The results are given in Table 22 where they are compared with the infarct size in each animal as determined by the MRI test, and also in FIG. 21. It can be seen that those animals with the least neurological scores were those treated with [R](+)PAI Mesylate. The neurological score was reduced by 54% and the infarct size by 36% in [R](+)PAI Mesylate-treated MCAO rats as compared to untreated ones.
    TABLE 22
    Neurological score of Rats submitted to MCA-Occlusion and [R](+)PAI
    Mesylate treatment with relation to their ischaemic infarct size.
    MCA-O MCA-O + [R](+)PAI Mesylate***
    Animal Neurological* Infarct size** Animal Neurological* Infarct size**
    No. Score (mm3) No. Score (mm3)
    1 5.0 201 1 1.0 137
    2 5.0 221 2 2.0 174
    3 6.0 358 3 4.0 164
    4 6.0 265 4 4.0 171
    5 8.25 341 5 2.88 215
    6 5.75 236
    MEAN + SD 6.0 ± 1.19 270 ± 65 MEAN + SD 2.78 ± 1.3 172 ± 28
    Neurological Score Infarct Size
    t = 4.25 t = 3.34
    f = 9 f = 9
    P < 0.01 p < 0.01
    [R](+)PAI Mesylate reduces the neurological score by 53.7% and infarct size by 36.3%.
    *Examined 24 hrs after MCA-Occlusion.
    **Evaluated by MRI T2-SCAN 48 hrs after MCA-Occlusion.
    ***[R](+)PAI Mesylate administered:
    Time after MCA-Occlusion:
     0 1.0 mg/kg ip;
     2 hrs 0.5 mg/kg ip;
    24 hrs 1.0 mg/kg ip.
    • REFERENCES FOR EXAMPLE 38
    • Cechetto D F, Wilson J X, Smith K E, Wolski D, Silver M D, Hachinski V C (1989). Autonomic and myocardial changes in middle cerebral artery occlusion: stroke models in the rat. Brain Res 502:296-305.
    • Kolb B, Sutherland R J, Whishaw I Q (1983). A comparison of the contributions of the frontal and parietal association cortex to spatial localizations in the rat. Behav. Neurosci. 97:13-27.
    • Menzies S A, Hoff J T, Betz A L (1992). Middle cerebral artery occlusion in rats: A neurological and pathological evaluation of a reproducible model. Neurosurgery 31:100-106.
    • Sauer D, Allegrini P R, Cosenti A, Pataki A, Amaceker H, Fagg G E (1993). Characterization of the cerebroprotective efficacy of the competitive NMDA receptor. antagonist CGP40116 in a rat model of focal cerebral ischemia: An in vivo magnetic resonance imaging study. J. Cerebr. Blood. Flow and Metabol. 13:595-602.
    • Stephanovich C, Editor, Stroke: Animal Models, Pergamon Press, 1983
    • Tamura A, Graham D I, McCulloch J, Teasdale G H (1981). Focal cerebral ischemia in the rat: 1. Description of technique and early neuropathological consequences following MCA occlusion. J. Cereb. Blood Flow and Metab. 1:53-60.
    • Teasdale G, Tyson G, Tamura A, Graham D I, McCulloch J. Focal cerebral ischaemia in the rat: Neuropatholgy, local cerebral blood flow and cerebrovascular permeability. In Stroke: Animal Models, Stephanovic C, Editor, Pergamon Press 1983, pp. 83-97.
    • Yamamoto M, Tamura A, Kirino T. Shimitzu M, Sano K (1988). Behavioral changes after focal cerebral ischemia by left middle cerebral artery occlusion in rats. Brain Re. 452:323-328
    • Yamori Y et al. (1976). Pathogenic similarity of strokes in stroke prone spontaneously hypertensive rats and humans. Stroke 7:46-53.
    • Young W, DeCrescito V, Flamm E S, Hadani M, Rappaport H, Cornu P (1986). Tissue Na, K, and Ca changes in regional cerebral ischemia: Their measurement and interpretation. Central Nervous System Trauma, 3:215-234.

Claims (28)

1. An oral pharmaceutical dosage form comprising rasagiline and adapted to retard or inhibit the release of rasagiline in the stomach.
2. The oral pharmaceutical dosage form of claim 1 that is a tablet, a capsule, or a core sheathed in an annular body.
3. The pharmaceutical dosage form of claim 2 that is a tablet.
4. The pharmaceutical dosage form of claim 2 comprising an enteric coating.
5. The pharmaceutical dosage form of claim 2 that is a core sheathed in an annular body.
6. The pharmaceutical dosage form of claim 5, wherein the core is a tablet.
7. The pharmaceutical dosage form of any of claim 5, wherein the annular body is an annular sheath.
8. The pharmaceutical dosage form of any of claim 6, wherein the core has an enteric coating.
9. The pharmaceutical dosage form of claim 2 that is a capsule.
10. The pharmaceutical dosage form of claim 9 comprising solid inactive particles.
11. The pharmaceutical dosage form of claim 10 wherein the particles are spheres, microparticles, nanoparticles or pellets made by spheronization, or a mixture thereof.
12. The pharmaceutical dosage form of claim 11 wherein the particles are spheres.
13. The pharmaceutical dosage form of claim 10, wherein the particles are comprised of sugars, alcohols, polyols or celluloses, or mixtures thereof.
14. The pharmaceutical dosage form of claim 13 wherein the particles are comprised of sugars.
15. The pharmaceutical dosage form of afy claim 10, wherein the solid inactive particles comprise rasagiline.
16. The pharmaceutical dosage form of claim 15, wherein the particles are coated with rasagiline.
17. The pharmaceutical dosage form of claim 10, wherein the particles comprise an enteric coating.
18. The pharmaceutical dosage form of claim 4, wherein the enteric coating comprises polymeric methacrylate.
19. The pharmaceutical dosage form of claim 18, wherein the polymeric methacrylate is methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30 percent.
20. The pharmaceutical dosage form of claim 4, wherein the enteric coating further comprises a plasticizer.
21. The pharmaceutical dosage form of claim 20 wherein the plasticizer is triethyl citrate.
22. The oral pharmaceutical dosage form of claim 1, wherein, upon administration to a patient, the rasagiline is released substantially in the intestinal tract.
23. The oral pharmaceutical dosage form of claim 22, wherein the rasagiline is released substantially in the small intestine.
24. The pharmaceutical dosage form of claim 1 having a rasagiline release profile in a United States Pharmacopoeia Apparatus II of less than 10% dissolution in 500 ml 0.1N HCl at 37° C. and 50 rpm after 3 hours, and more than 90% dissolution in phosphate buffer at a pH of 6.8 after an additional 2 hours.
25. A method of treating a patient suffering from Parkinson's disease, brain ischemia, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, multiple sclerosis, schizophrenia, or an affective illness, comprising administering to the patient the oral dosage form of claim 1.
26. The method of claim 25 for treating a patient suffering from Parkinson's disease.
27. The method of claim 26, wherein the patient presents impaired gastric motility.
28-33. (canceled)
US11/155,864 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof Abandoned US20060094783A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/155,864 US20060094783A1 (en) 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US11/595,726 US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IL9295290A IL92952A (en) 1990-01-03 1990-01-03 R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL92,952 1990-01-03
US63218490A 1990-12-21 1990-12-21
US08/063,455 US5387612A (en) 1990-01-03 1993-05-18 Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
US13951793A 1993-10-18 1993-10-18
US08/411,398 US5532415A (en) 1990-01-03 1995-03-28 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US08/446,439 US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
PCT/US1996/007465 WO1996037199A1 (en) 1995-05-22 1996-05-22 Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof
US08/952,705 US6316504B1 (en) 1993-10-18 1996-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/016,268 US6630514B2 (en) 1993-10-18 2001-10-26 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/305,478 US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US11/155,864 US20060094783A1 (en) 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/305,478 Continuation US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/595,726 Continuation US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Publications (1)

Publication Number Publication Date
US20060094783A1 true US20060094783A1 (en) 2006-05-04

Family

ID=23772591

Family Applications (6)

Application Number Title Priority Date Filing Date
US08/446,439 Expired - Lifetime US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US08/952,705 Expired - Lifetime US6316504B1 (en) 1990-01-03 1996-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/016,268 Expired - Fee Related US6630514B2 (en) 1990-01-03 2001-10-26 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/305,478 Expired - Fee Related US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US11/155,864 Abandoned US20060094783A1 (en) 1990-01-03 2005-06-17 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US11/595,726 Abandoned US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US08/446,439 Expired - Lifetime US5744500A (en) 1990-01-03 1995-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US08/952,705 Expired - Lifetime US6316504B1 (en) 1990-01-03 1996-05-22 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/016,268 Expired - Fee Related US6630514B2 (en) 1990-01-03 2001-10-26 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US10/305,478 Expired - Fee Related US6956060B2 (en) 1990-01-03 2002-11-27 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/595,726 Abandoned US20070100001A1 (en) 1990-01-03 2006-11-10 Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof

Country Status (22)

Country Link
US (6) US5744500A (en)
EP (1) EP0828485A4 (en)
JP (1) JP3341898B2 (en)
KR (1) KR100412154B1 (en)
CN (1) CN1096853C (en)
AU (1) AU699090B2 (en)
BR (1) BR9608733A (en)
CA (1) CA2221458A1 (en)
CZ (1) CZ288724B6 (en)
EE (1) EE03741B1 (en)
HK (1) HK1015269A1 (en)
HU (1) HUP9901629A3 (en)
IL (1) IL118247A (en)
LT (1) LT4455B (en)
LV (1) LV12083B (en)
MX (1) MX9708977A (en)
NO (1) NO975331L (en)
NZ (1) NZ308866A (en)
PL (1) PL184124B1 (en)
RU (1) RU2203653C2 (en)
SK (1) SK283675B6 (en)
WO (1) WO1996037199A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
US20070112217A1 (en) * 2005-11-17 2007-05-17 Anton Frenkel Methods for isolating propargylated aminoindans
US20070232700A1 (en) * 2006-04-03 2007-10-04 Eran Blaugrund Use of rasagilline for the treatment of restless legs syndrome
US20080146676A1 (en) * 2006-12-14 2008-06-19 Anton Frenkel Tannate salt of rasagiline
WO2008076348A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20080261894A1 (en) * 2005-02-17 2008-10-23 Rivka Kreitman Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US20090076160A1 (en) * 2007-09-17 2009-03-19 Balazs Lendvai Use of R (+) -N-propargyl-1-aminoindan to treat or prevent hearing loss
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US20090312436A1 (en) * 2008-06-13 2009-12-17 Ruth Levy Rasagiline for parkinson's disease modification
US20090318564A1 (en) * 2008-06-19 2009-12-24 Anton Frenkel Process for preparing and drying solid rasagiline base
US20100010095A1 (en) * 2008-06-19 2010-01-14 Anton Frenkel Process for purifying rasagiline base
US20100137447A1 (en) * 2007-04-30 2010-06-03 Ratiopharm Gmbh Method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US20110155626A1 (en) * 2009-11-26 2011-06-30 Usv Limited Process for preparation of rasagiline and salts thereof
US8143315B2 (en) 2006-08-18 2012-03-27 Ratiopharm Gmbh Salts of the active substance rasagiline
US20130089610A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. R(+)-n-methyl-propargyl-aminoindan
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
US8946482B2 (en) 2009-07-09 2015-02-03 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline
US9346746B2 (en) 2011-10-10 2016-05-24 Teva Pharmaceutical Industries, Ltd. R(+)-N-formyl-propargyl-aminoindan

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5726969A (en) * 1994-12-28 1998-03-10 Matsushita Electric Industrial Co., Ltd. Optical recording medium having dual information surfaces
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
EP1242066B1 (en) 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
NZ532583A (en) 2001-11-05 2006-12-22 Krele Pharmaceuticals Compositions and methods for increasing compliance using aldehyde dehydrogenase inhibitors ( ALDH ) such as disulfiram and monoamine oxidase B inhibitors ( MAOB ) such as selegiline
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
JP4757024B2 (en) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド Neuroprotective iron chelating agent and pharmaceutical composition containing the same
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
CN1605336A (en) 2003-10-10 2005-04-13 中国医学科学院药物研究所 Application of L-butylphthalide in the process for preparing cerebral infarction preventing and treating medicine
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (en) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS AND DISEASES
JP2005232148A (en) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd Use of propargylamine as neuroprotective agent
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
WO2006014968A2 (en) * 2004-07-27 2006-02-09 Teva Pharmaceutical Industries, Ltd. Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
DK2332408T3 (en) 2005-02-17 2013-12-02 Biogen Idec Inc Treatment of neurological diseases
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2600603A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Formulations of ladostigil tartrate
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma Use of ladostigil for the treatment of multiple sclerosis
FR2886549B1 (en) * 2005-06-06 2007-09-07 Biocodex PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CEREBRAL EDEMA
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
CA2634166C (en) * 2005-12-09 2016-03-29 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
US20110047685A1 (en) * 2006-02-16 2011-03-03 Ferrara Vincent R Impact energy management method and system
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CN101062897B (en) * 2006-04-25 2011-11-23 重庆医药工业研究院有限责任公司 Improved process for preparing 2,3-dihydro-1H-indenes-1-amine and derivative thereof
BRPI0905680A2 (en) * 2008-01-11 2015-07-07 Teva Pharma "pharmaceutical composition of a pharmaceutical composition"
WO2009118657A2 (en) * 2008-03-28 2009-10-01 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
CA2812006C (en) * 2008-06-02 2016-07-26 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
JP5639999B2 (en) * 2008-06-02 2014-12-10 ジェネリクス・［ユーケー］・リミテッド Improved process for the preparation of amines
JP2011524353A (en) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline soft gelatin capsule
EA201170181A1 (en) 2008-07-11 2011-08-30 Синтон Бв POLYMORPHIC FORMS OF RAZAGILINA HYDROCHLORIDE
US20110263719A1 (en) * 2008-07-30 2011-10-27 Vinayak Gore Polymorphic form of rasagiline mesylate
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
AU2010233694A1 (en) * 2009-04-09 2011-09-29 Merck Sharp & Dohme B.V. Indane derivatives
CN102048717B (en) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 Stable rasagiline composition
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
CA2785501A1 (en) 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
DK2531181T3 (en) 2010-02-03 2019-07-15 Pharma Two B Ltd FORMULATIONS OF RASAGILIN WITH EXTENDED DELIVERY AND USES THEREOF
EA023786B1 (en) 2010-04-30 2016-07-29 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propynylaminoindan transdermal compositions
JP6355921B2 (en) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. Treatment of addiction to cocaine
MX2013004598A (en) 2010-10-26 2013-07-17 Teva Pharma Deuterium enriched rasagiline.
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US9119799B2 (en) 2011-03-24 2015-09-01 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
EA201491734A1 (en) 2012-03-21 2015-01-30 Синтон Бв STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING RAZAGILINA SALTS
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
KR20150059177A (en) 2012-11-02 2015-05-29 테이코쿠 팔마 유에스에이, 인코포레이티드 Propynylaminoindan transdermal compositions
ES2502140T1 (en) * 2013-02-06 2014-10-02 Galenicum Health S.L. Rasagiline hemitartrate immediate-release tablets
ES2524865T1 (en) * 2013-02-06 2014-12-15 Galenicum Health S.L. Stable pharmaceutical compositions in the form of immediate-release tablets
US20160022572A1 (en) * 2013-03-13 2016-01-28 N To B Ltd. Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease
CN103804200B (en) * 2014-02-21 2015-04-29 常州市第四制药厂有限公司 Preparation method of rasagiline and analogue thereof
US11701340B2 (en) * 2019-04-17 2023-07-18 Vici Health Sciences., Llc Liquid pharmaceutical compositions

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
US3513244A (en) * 1966-07-16 1970-05-19 Aspro Nicholas Ltd Methods of lowering blood pressure in animals by administering secondary and tertiary amines
US4826875A (en) * 1986-06-10 1989-05-02 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4971995A (en) * 1988-02-05 1990-11-20 Delande S.A. Alkyl or benzyl phenol ethers, their preparation and their therapeutic uses
US5043347A (en) * 1986-08-21 1991-08-27 Roussel Uclaf Indanes and analgesic compositions and methods thereof
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5137730A (en) * 1990-04-23 1992-08-11 E. R. Squibb & Sons, Inc. Tablet composition and method for problem pharmaceutical materials using citric acid
US5196583A (en) * 1989-12-04 1993-03-23 Nippon Paint Co., Ltd. Propargyl amino compounds
US5225197A (en) * 1989-04-28 1993-07-06 Beecham Group Plc Pharmaceutical formulation
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5387612A (en) * 1990-01-03 1995-02-07 Teva Pharmaceutical Industries Ltd. Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
US5466464A (en) * 1991-12-24 1995-11-14 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
US5486541A (en) * 1991-10-16 1996-01-23 Teva Pharmaceutical Industries, Ltd. Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5792473A (en) * 1994-03-01 1998-08-11 Gerhard Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
US6126968A (en) * 1995-09-20 2000-10-03 Teva Pharmaceutical Industries, Ltd. Stable compositions containing N-propargyl-1-aminoindan
US20040127577A1 (en) * 2002-11-15 2004-07-01 Eran Blaugrund Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513244A (en) * 1894-01-23 Island
GB1037014A (en) 1963-08-02 1966-07-20 Aspro Nicholas Ltd Derivatives of 1-aminoindane
US3513249A (en) * 1968-12-24 1970-05-19 Ideal Ind Explosion connector with improved insulating means
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
HU197510B (en) 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
CA1327795C (en) 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
JPH04504760A (en) 1989-09-25 1992-08-20 アメリカ合衆国 Evaluation methods for detecting inflammatory responses and predicting responses to stress
ATE145551T1 (en) 1989-10-02 1996-12-15 Cima Labs Inc Effervescent DOSAGE FORM AND METHOD FOR ADMINISTRATION THEREOF
FR2655044B1 (en) 1989-11-24 1995-03-03 Delalande Sa DERIVATIVES OF (HETERO) ARYLMETHYLOXY-4 PHENYL TETRAZOLE AND OXADIAZOLE, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
SE501848C2 (en) 1992-11-18 1995-06-06 Kvaerner Pulping Tech Method to cook pulp continuously at constant temperature
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
TR199700878T1 (en) 1995-03-02 1998-01-21 R.P. Scherer Limited Pharmacological compositions containing inhibitors of monamine oxidase B.
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1052983A2 (en) * 1998-01-27 2000-11-22 Thomas N. Thomas Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
FI104042B (en) * 1998-09-29 1999-11-15 Aaro Kiuru Procedure for measuring lung perfusion
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60237372D1 (en) * 2001-07-04 2010-09-30 Sun Pharma Advanced Res Co Ltd MAGNETIC RETENTION SYSTEM WITH CONTROLLED MEDICINAL RELEASE
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060009483A1 (en) * 2002-05-31 2006-01-12 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
US20040115254A1 (en) * 2002-09-06 2004-06-17 Genteric, Inc. Microcapsules and methods of use
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
EP1848402B2 (en) * 2005-02-23 2019-02-20 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
US3513244A (en) * 1966-07-16 1970-05-19 Aspro Nicholas Ltd Methods of lowering blood pressure in animals by administering secondary and tertiary amines
US4826875A (en) * 1986-06-10 1989-05-02 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US5043347A (en) * 1986-08-21 1991-08-27 Roussel Uclaf Indanes and analgesic compositions and methods thereof
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
US4971995A (en) * 1988-02-05 1990-11-20 Delande S.A. Alkyl or benzyl phenol ethers, their preparation and their therapeutic uses
US5225197A (en) * 1989-04-28 1993-07-06 Beecham Group Plc Pharmaceutical formulation
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5196583A (en) * 1989-12-04 1993-03-23 Nippon Paint Co., Ltd. Propargyl amino compounds
US5457133A (en) * 1990-01-03 1995-10-10 Teva Pharmaceutical Industries Ltd. R-enantiomers of N-propargyl-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5891923A (en) * 1990-01-03 1999-04-06 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan for the treatment of dementia
US5387612A (en) * 1990-01-03 1995-02-07 Teva Pharmaceutical Industries Ltd. Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease
US5453446A (en) * 1990-01-03 1995-09-26 Teva Pharmaceutical Industries, Ltd. Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
US6956060B2 (en) * 1990-01-03 2005-10-18 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5519061A (en) * 1990-01-03 1996-05-21 Teva Pharmaceutical Industries Ltd. R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
US5532415A (en) * 1990-01-03 1996-07-02 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US5576353A (en) * 1990-01-03 1996-11-19 Teva Pharmaceutical Industries Ltd. Method of treating memory disorders using R-enantiomers of N-propargyl-aminoindan compounds
US5599991A (en) * 1990-01-03 1997-02-04 Teva Pharmaceutical Industries Ltd. Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5786390A (en) * 1990-01-03 1998-07-28 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of the R-enantiomer of N-propargyl -1-aminoindan
US5137730A (en) * 1990-04-23 1992-08-11 E. R. Squibb & Sons, Inc. Tablet composition and method for problem pharmaceutical materials using citric acid
US5486541A (en) * 1991-10-16 1996-01-23 Teva Pharmaceutical Industries, Ltd. Monofluorinated derivatives of N-propargyl-1-aminoindan and their use as inhibitors of monoamine oxidase
US5466464A (en) * 1991-12-24 1995-11-14 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US6316504B1 (en) * 1993-10-18 2001-11-13 Technion Research And Development Foundation, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US6630514B2 (en) * 1993-10-18 2003-10-07 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5792473A (en) * 1994-03-01 1998-08-11 Gerhard Gergely Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
US6126968A (en) * 1995-09-20 2000-10-03 Teva Pharmaceutical Industries, Ltd. Stable compositions containing N-propargyl-1-aminoindan
US20040127577A1 (en) * 2002-11-15 2004-07-01 Eran Blaugrund Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
US20080261894A1 (en) * 2005-02-17 2008-10-23 Rivka Kreitman Combination Therapy with Glatiramer Acetate and Rasagiline for the Treatment of Multiple Sclerosis
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US20070112217A1 (en) * 2005-11-17 2007-05-17 Anton Frenkel Methods for isolating propargylated aminoindans
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7598420B1 (en) 2005-12-06 2009-10-06 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US7619117B1 (en) 2005-12-06 2009-11-17 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
US20070232700A1 (en) * 2006-04-03 2007-10-04 Eran Blaugrund Use of rasagilline for the treatment of restless legs syndrome
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
US8143315B2 (en) 2006-08-18 2012-03-27 Ratiopharm Gmbh Salts of the active substance rasagiline
US20100145101A1 (en) * 2006-12-14 2010-06-10 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
US20080161408A1 (en) * 2006-12-14 2008-07-03 Anton Frenkel Crystalline solid rasagiline base
US7547806B2 (en) 2006-12-14 2009-06-16 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
WO2008076348A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
US20080146676A1 (en) * 2006-12-14 2008-06-19 Anton Frenkel Tannate salt of rasagiline
EA016820B1 (en) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Crystalline solid rasagiline base
US8614252B2 (en) 2006-12-14 2013-12-24 Teva Pharmaceutical Industries Ltd. Crystalline solid rasagiline base
US7750051B2 (en) 2006-12-14 2010-07-06 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
US20100144887A1 (en) * 2006-12-14 2010-06-10 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
US20100137447A1 (en) * 2007-04-30 2010-06-03 Ratiopharm Gmbh Method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
JP2010539235A (en) * 2007-09-17 2010-12-16 テバ ファーマシューティカル インダストリーズ リミティド R (+)-N-propargyl-1-aminoindan for treating or preventing hearing loss
WO2009038732A1 (en) * 2007-09-17 2009-03-26 Teva Pharmaceutical Industries, Ltd. Use of r(+)-n-propargyl-1-aminoindan to treat or prevent hearing loss
US20090076160A1 (en) * 2007-09-17 2009-03-19 Balazs Lendvai Use of R (+) -N-propargyl-1-aminoindan to treat or prevent hearing loss
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20090312436A1 (en) * 2008-06-13 2009-12-17 Ruth Levy Rasagiline for parkinson's disease modification
US20100010095A1 (en) * 2008-06-19 2010-01-14 Anton Frenkel Process for purifying rasagiline base
AU2009260728B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
EA021472B1 (en) * 2008-06-19 2015-06-30 Тева Фармасьютикал Индастриз, Лтд. Process for preparing and drying solid rasagiline base
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
WO2009154777A3 (en) * 2008-06-19 2010-05-06 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US8163960B2 (en) 2008-06-19 2012-04-24 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US20090318564A1 (en) * 2008-06-19 2009-12-24 Anton Frenkel Process for preparing and drying solid rasagiline base
US20100189787A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline citrate formulation
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
US20100190859A1 (en) * 2009-01-23 2010-07-29 Anton Frenkel Citrate Salt of Rasagiline
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US7855233B2 (en) 2009-01-23 2010-12-21 Teva Pharmaceutical Industries, Ltd. Citrate salt of Rasagiline
US8946482B2 (en) 2009-07-09 2015-02-03 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
US8741962B2 (en) * 2009-11-26 2014-06-03 Usv Limited Process for preparation of Rasagiline and salts thereof
US20110155626A1 (en) * 2009-11-26 2011-06-30 Usv Limited Process for preparation of rasagiline and salts thereof
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
WO2013055689A1 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
US20130089610A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. R(+)-n-methyl-propargyl-aminoindan
US9339469B2 (en) * 2011-10-10 2016-05-17 Teva Pharmaceutical Industries, Ltd. R(+)-N-methyl-propargyl-aminoindan
US9346746B2 (en) 2011-10-10 2016-05-24 Teva Pharmaceutical Industries, Ltd. R(+)-N-formyl-propargyl-aminoindan
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Also Published As

Publication number Publication date
NO975331D0 (en) 1997-11-20
PL184124B1 (en) 2002-09-30
AU699090B2 (en) 1998-11-19
KR100412154B1 (en) 2004-07-05
HUP9901629A2 (en) 2000-02-28
NZ308866A (en) 1999-09-29
LT97200A (en) 1998-09-25
IL118247A (en) 2002-07-25
EP0828485A4 (en) 1998-12-02
SK283675B6 (en) 2003-11-04
KR19990021896A (en) 1999-03-25
NO975331L (en) 1998-01-20
US6956060B2 (en) 2005-10-18
CZ288724B6 (en) 2001-08-15
WO1996037199A1 (en) 1996-11-28
CZ369997A3 (en) 1999-06-16
MX9708977A (en) 1998-03-31
BR9608733A (en) 1999-12-07
HUP9901629A3 (en) 2000-03-28
US20070100001A1 (en) 2007-05-03
EE03741B1 (en) 2002-06-17
HK1015269A1 (en) 1999-10-15
LT4455B (en) 1999-01-25
AU5872396A (en) 1996-12-11
EP0828485A1 (en) 1998-03-18
LV12083B (en) 1998-09-20
US5744500A (en) 1998-04-28
LV12083A (en) 1998-07-20
US20030212145A1 (en) 2003-11-13
US20030065038A1 (en) 2003-04-03
EE9700310A (en) 1998-06-15
PL323470A1 (en) 1998-03-30
CA2221458A1 (en) 1996-11-28
CN1096853C (en) 2002-12-25
US6316504B1 (en) 2001-11-13
RU2203653C2 (en) 2003-05-10
WO1996037199A8 (en) 1999-08-12
SK157497A3 (en) 1998-05-06
CN1191481A (en) 1998-08-26
IL118247A0 (en) 1996-09-12
JP3341898B2 (en) 2002-11-05
JP2000508292A (en) 2000-07-04
US6630514B2 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
US6316504B1 (en) Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5599991A (en) Esylate and sulfate salts of R(+)-N-propargyl-1-aminoindan
EP0812190B1 (en) R-enantiomer of n-propargyl-1-aminoindan for the treatment of various diseases and mesylate, esylate and sulfate thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载